| Date | Title | | | | 12/30/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – December 30, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 30, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on December 29, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 454,006,720 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Share... |
| |  | | 12/23/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – December 23, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 23, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on December 22, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 453,883,765 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Share... |
| | | | 12/22/14 | Medtronic Drug-Coated Balloon for Peripheral Artery Disease Tops Standard Balloon Angioplasty in Landmark Study| Results of IN.PACT SFA Trial Published in Circulation MINNEAPOLIS -- Dec. 22, 2014 -- The results of a landmark study published this month in Circulation, the world's leading cardiovascular journal, indicate that a novel medical device from Medtronic, Inc. (NYSE: MDT) called the IN.PACT Admiral drug-coated balloon (DCB) significantly outperformed standard balloon angioplasty in the treatment of symptomatic peripheral artery disease in the upper leg -- specifically, the superficial femoral and p... |
|  | | | 12/19/14 | Covidien Declares Quarterly Cash Dividend| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 19, 2014--
Covidien
plc (NYSE: COV) today announced that its Board of Directors has
declared a quarterly cash dividend of $0.36 per ordinary share. The
quarterly dividend is payable on Jan. 16, 2015, to shareholders of
record on Jan. 2, 2015.
About Covidien
Covidien is a global health care leader that understands the challenges
faced by providers and their patients and works to address ... |
| | | | 12/19/14 | Medtronic Completes Global User Evaluations for New Insulin Pump Platform| Next-Generation System with Breakthrough Advancement in Closed-Loop Technology Furthers Global Innovation MINNEAPOLIS - December 19, 2014 - Medtronic, Inc. (NYSE:MDT) today announced it has completed global user evaluations of a next generation system that uses the new pump platform and represents a key step toward development of an artificial pancreas. The completely redesigned insulin delivery system comes with new features that offer convenience in managing diabetes and improved design eleme... |
| | | | 12/17/14 | New Study Shows Addition of Stent Thrombectomy More Effective Than Traditional Pharmaceutical Treatment for Acute Ischemic Stroke Patients| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 17, 2014--
In a landmark study evaluating the addition of stent thrombectomy clot
removal to pharmaceutical treatment for patients suffering an acute
ischemic stroke (AIS), stent thrombectomy provided a significant
clinical benefit when compared to pharmaceutical treatment alone.
Results from the Multi
center Randomized Clinical trial of Endovascular treatment for Acute
ischemic stroke in the Netherlands (MR ... |
| | | | 12/17/14 | Covidien’s Unique Capsule Endoscopy PillCam® SB Featured in New Smithsonian Exhibit ‘Tools: Extending Our Reach’| Innovative design of wireless, vitamin-sized capsule recognized for
its profound impact on improving the standard-of-care for small bowel
examinations
NEW YORK--(BUSINESS WIRE)--Dec. 17, 2014--
PillCam® SB, Covidien’s wireless capsule endoscope, is
now featured in the exhibit, “Tools:
Extending Our Reach” at New York’s Cooper Hewitt Smithsonian Design
Museum. PillCam SB is one of 175 installations highlighting how tools
and innovations ... |
| | | | 12/16/14 | Three Colorado Agencies Receive Medtronic Health Access Grant| Medtronic Philanthropy Grants Support Local Organizations Committed to Expanding Access to Healthcare for the Underserved MINNEAPOLIS - December 16, 2014 - Rocky Mountain Youth Clinics, Roundup River Ranch and the Parkinson Association of the Rockies each received a two-year $50,000 Health Access Grant from Medtronic Philanthropy in recognition of their continued commitment to improve access to healthcare. Each was nominated by a team of Medtronic employees working in Louisville, CO. Rocky M... |
| | | | 12/15/14 | Medtronic Launches NovaShield(TM) Injectable Nasal Packing and Stent for Functional Endoscopic Sinus Surgery (FESS) | NovaShield(TM) Offers Convenient Tool to Control Minimal Bleeding, Prevent Adhesions, and Provide Antibacterial Effectiveness after FESS* MINNEAPOLIS - December 15, 2014 - Medtronic (NYSE: MDT) today announced the launch of the NovaShield(TM) Injectable Nasal Packing and Stent for functional endoscopic sinus surgery (FESS), manufactured by the company's Ear Nose and Throat (ENT) division of its Surgical Technologies business. Made from chitosan, NovaShield is a ready-to-use gel placed in the s... |
| | | | 12/11/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – December 11, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 11, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on December 10, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 453,773,707 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Share... |
| | | | 12/11/14 | Medtronic Receives FDA Approval and Launches Two New Cardiac Resynchronization Therapy Quadripolar Leads| Additional Attain Performa® Quadripolar Leads Provide Physicians with More Options to Optimize Delivery of Proven Heart Failure Treatment MINNEAPOLIS - Dec. 11, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval and commercial launch of two additional Attain Performa® left ventricular (LV) quadripolar leads, which can be paired with the Medtronic Viva® Quad XT and Viva® Quad S cardiac resynchronization therapy defibrillators (CRT-D) to treat... |
| | | | 12/09/14 | Endurant 'AAA' Stent Graft from Medtronic Continues to Deliver Durable, Consistent and Proven Outcomes| Latest Results from Two Clinical Studies Show Strong Mid-Term Performance of Leading Medical Device for Endovascular Repair of Abdominal Aortic Aneurysms MINNEAPOLIS -- Dec. 9, 2014 -- For endovascular repair of abdominal aortic aneurysms, the Endurant AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to deliver durable, consistent and proven outcomes, according to the latest results from two clinical studies. The Endurant AAA stent graft system has been used to treat more... |
| | | | 12/09/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – December 9, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 9, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on December 8, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 453,612,034 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Shares ... |
| | | | 12/08/14 | The Bakken Invitation Announces 2014 Honorees: 10 Inspiring People Who Live On and Give On| Medtronic Philanthropy Program Honors Ten Individuals Around the World with $20,000 Charitable Grants to Their Causes MINNEAPOLIS - December 8, 2014 - Medtronic (NYSE: MDT) today announced the names of 10 people from around the world who will be honored as part of the Bakken Invitation, a global program launched in 2013 that celebrates and connects people who, with the help of medical technology, have overcome health challenges and are now making a difference in their communities. The Bakken ... |
| | | | 12/08/14 | Medtronic Issues $250,000 in Health Access Grants to Support Diabetes Services for the Underserved of San Antonio| Grants Help Mark Five Years Since Diabetes Therapy Management and Education Center Opened its Doors SAN ANTONIO, TX - December 8, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that five San Antonio community organizations will receive a combined $250,000 in Health Access Grants in recognition of their continued commitment to promoting healthy lifestyles and improving access to healthcare, with an emphasis on diabetes. As Medtronic marks the five year anniversary of its San Antonio location... |
| | | | 12/05/14 | Medtronic CFO Gary Ellis to Speak at Oppenheimer Healthcare Conference| MINNEAPOLIS - Dec 5, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 25th Annual Oppenheimer Healthcare Conference on Wednesday, December 10, 2014, in New York. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 9:10 a.m. EST (8:10 a.m. CST). A live audio webcast of the presentation will be available on December 10, 2014, by clicking o... |
| | | | 12/05/14 | Form 8.1 – Covidien| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 5, 2014--
Covidien plc:
FORM 8.1(a)&(b)(i)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL
ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM
FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
Name of person dealing (Not... |
| | | | 12/05/14 | Form 8.1 - Covidien| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 5, 2014--
FORM 8.1(a)&(b)(i)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL
ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM
FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
Name of person dealing (Note 1)
... |
| | | | 12/05/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – December 5, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 5, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on December 4, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 453,450,240 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Shares ... |
| | | | 12/04/14 | Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2015| MINNEAPOLIS - December 4, 2014 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.305 per share of the Company's common stock. The dividend is payable on January 16, 2015, to shareholders of record at the close of business on January 2, 2015. About MedtronicMedtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the ... |
| | | | 12/04/14 | HeartWare Presentation At The Oppenheimer 25th Annual Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., Dec. 4, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference at 10:20 a.m. EST on Wednesday, December 10, 2014. The conference is being held December 10-11, 2014 at the Crowne Plaza Hotel in New York C... |
| | | | 12/04/14 | Chinese Ministry of Commerce Clears Medtronic Acquisition of Covidien| MINNEAPOLIS AND DUBLIN, Ireland - Dec. 4, 2014 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced that the Chinese Ministry of Commerce has cleared Medtronic's proposed acquisition of Covidien. The proposed acquisition has also been cleared by the South Korean Fair Trade Commission and all necessary antitrust clearances have now been obtained. The transaction is expected to close in early 2015 after approvals by both compan... |
| | | | 12/04/14 | Chinese Ministry of Commerce Clears Medtronic Acquisition of Covidien | MINNEAPOLIS AND DUBLIN, Ireland - Dec. 4, 2014 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced that the Chinese Ministry of Commerce has cleared Medtronic's proposed acquisition of Covidien. The proposed acquisition has also been cleared by the South Korean Fair Trade Commission and all necessary antitrust clearances have now been obtained. The transaction is expected to close in early 2015 after approvals by both compan... |
| | | | 12/04/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – December 4, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 4, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on December 3, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 453,218,565 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Shares ... |
| | | | 12/03/14 | Medtronic Releases 2014 Integrated Performance Report| "Delivering Societal Value through Responsible Growth" Reviews Company's Economic, Social and Environmental Performance for Fiscal Year 2014 MINNEAPOLIS - Dec. 3, 2014 - Medtronic, Inc. (NYSE:MDT) has released "Delivering Societal Value through Responsible Growth," the company's 2014 Integrated Performance Report. The company's first integrated report provides a comprehensive view of how Medtronic creates value to society through its efforts to increase global access to care... |
| | | | 12/03/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – December 3, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 3, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on December 2, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 453,075,299 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Shares ... |
| | | | 12/02/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – December 2, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Dec. 2, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on December 1, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 452,832,461 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Shares ... |
| | | | 12/01/14 | Medtronic Prices $17 Billion in Private Placement of Senior Notes| MINNEAPOLIS - December 1, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the pricing of $17 billion aggregate principal amount of senior notes in seven tranches, as follows: Description Amount Maturity Floating Rate Senior Notes* $500,000,000 Due March 15, 2020 1.500 percent Senior Notes $1,000,000,000 Due March 15, 2018 2.500 percent Senior Notes $2,500,000,000 Due March 15, 2020 3.150 percent Senior Notes $2,500,000,000 Due ... |
| | | | 11/28/14 | European Commission Clears Medtronic Acquisition of Covidien | MINNEAPOLIS AND DUBLIN, Ireland – Nov. 28, 2014 – Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced that the European Commission has conditionally cleared Medtronic’s proposed acquisition of Covidien. The clearance decision is conditional on Medtronic’s commitment to divest Covidien’s drug coated balloon business. As previously announced, a subsidiary of Covidien entered into an agreement to divest Covidien’s drug coated balloon busin... |
| | | | 11/28/14 | European Commission Clears Medtronic Acquisition of Covidien|
MINNEAPOLIS AND DUBLIN, Ireland - Nov. 28, 2014 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced that the European Commission has conditionally cleared Medtronic's proposed acquisition of Covidien. The clearance decision is conditional on Medtronic's commitment to divest Covidien's drug coated balloon business. As previously announced, a subsidiary of Covidien entered into an agreement to divest Covidien's drug coated balloon busin... |
| | | | 11/26/14 | Medtronic Acquisition of Covidien Receives U.S. FTC Clearance| MINNEAPOLIS AND DUBLIN, Ireland - Nov. 26, 2014 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced the receipt of U.S. Federal Trade Commission (FTC) clearance of Medtronic's proposed acquisition of Covidien. "This regulatory clearance represents an important milestone in bringing our companies together," said Omar Ishrak, Chairman and CEO of Medtronic. "We continue to make good progress in planning for the integration of these two companies which will u... |
| | | | 11/26/14 | Medtronic Acquisition of Covidien Receives U.S. FTC Clearance| MINNEAPOLIS AND DUBLIN, Ireland – Nov. 26, 2014 – Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) today announced th e receipt of U.S. Federal Trade Commission (FTC) clearance of Medtronic’s proposed acquisition of Covidien.
“This regulatory clearance represents an important milestone in bringing our companies together,” said Omar Ishrak, Chairman and CEO of Medtronic. “We continue to make good progress in planning for the integration of these two... |
| | | | 11/24/14 | Covidien’s Fortrex™ PTA Balloon Receives FDA 510(k) Clearance| Fortrex™ PTA Balloon Facilitates Arteriovenous Access in
Patients Receiving Hemodialysis for Chronic Kidney Disease
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 24, 2014--
Covidien plc (NYSE: COV) today announced U.S. Food and Drug
Administration 510(k) clearance for its Fortrex™ over-the-wire (OTW)
percutaneous transluminal angioplasty (PTA) balloon catheter. The
Fortrex™ 0.035” OTW PTA balloon catheter —the next-generation high
pressure solution t... |
| | | | 11/21/14 | Covidien Announces Mailing of Definitive Joint Proxy Statement/Prospectus| DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 21, 2014--
Covidien
plc (NYSE: COV) today announced, for purposes of the Irish Takeover
Rules, that the definitive joint proxy statement of Covidien plc and
Medtronic, Inc., which also serves as a prospectus of Medtronic Holdings
Limited
and comprises Covidien’s scheme circular required under Irish
law, is being sent today to
Covidien and Medtronic, Inc. shareholders.
As previously ann... |
| | | | 11/20/14 | Covidien Achieves CE Mark for the Nellcor™ Bedside SpO2 Patient Monitoring System, PM100N| New device is the only commercially available bedside monitor
designed for home care and sleep study settings
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 20, 2014--
Covidien
(NYSE: COV) today announced CE Mark approval for its Nellcor™ Bedside SpO2
Patient Monitoring System, PM100N. The system currently is available in
the European Economic Area (EEA), Australia and New Zealand. The
Nellcor™ Bedside SpO2 Patient Monitoring System is the only
... |
| | | | 11/19/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – November 19, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 19, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on November 18, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 452,731,347 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Share... |
| | | | 11/18/14 | Medtronic Reports Second Quarter Earnings| Revenue of $4.4 Billion Grew 5% on Constant Currency Basis; 4% as Reported
Non-GAAP Diluted EPS of $0.96, Growth of 5%; GAAP Diluted EPS of $0.83, Decline of 7%
Company Updates FY15 Revenue Growth Outlook; Reiterates FY15 EPS Guidance
Company Reaffirms Commitment to Covidien Transaction
MINNEAPOLIS - Nov. 18, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its second quarter of fiscal year 2015, which ended October 24, 2014.
The company reported worldwide seco... |
| | | | 11/17/14 | Medtronic and Covidien Shareholder Meetings Scheduled for January 6, 2015| MINNEAPOLIS & DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 17, 2014--
Medtronic,
Inc. (NYSE: MDT) and Covidien plc
(NYSE: COV) announced that following a hearing today before the Irish
High Court the companies have scheduled shareholder meetings for
Tuesday, January 6, 2015, in connection with the pending acquisition of
Covidien by Medtronic.
Medtronic’s special shareholder meeting will be held on January 6, 2015
at 8:00 a.m. local ti... |
| | | | 11/17/14 | Medtronic and Covidien Shareholder Meetings Scheduled for January 6, 2015| MINNEAPOLIS AND DUBLIN - Nov. 17, 2014 - Medtronic, Inc. (NYSE: MDT) and Covidien plc (NYSE: COV) announced that following a hearing today before the Irish High Court the companies have scheduled shareholder meetings for Tuesday, January 6, 2015, in connection with the pending acquisition of Covidien by Medtronic. Medtronic's special shareholder meeting will be held on January 6, 2015 at 8:00 a.m. local time at the Hyatt Regency, 1300 Nicollet Mall, Minneapolis, MN, 55403. This meeting is bei... |
| | | | 11/16/14 | Medtronic Studies Show Cardiac Resynchronization Therapy Extends Life, Reduces Hospital Readmissions| Data Demonstrate Clinical and Economic Value of Underutilized Treatment for Heart Failure Patients at American Heart Association's Scientific Sessions 2014 MINNEAPOLIS and CHICAGO - Nov. 16, 2014 - Medtronic, Inc. (NYSE: MDT) today announced new data supporting the clinical and economic value of its cardiac resynchronization therapy (CRT) devices for the treatment of heart failure, including a significant reduction in all-cause 30-day readmissions after heart failure hospitalizations. Additiona... |
| | | | 11/13/14 | Six Month Results of VeClose Study Demonstrate Safety, Effectiveness of the VenaSealTM Closure System| Data Demonstrate Strong Closure Rates in Patients with Chronic
Venous Insufficiency, Varicose Veins
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 13, 2014--
Covidien plc (NYSE:COV) today announced the six-month results of the
VeClose pivotal study, which demonstrated the safety and effectiveness
of the VenaSeal™ closure system* in patients with chronic venous
insufficiency (CVI) having symptomatic reflux in the great saphenous
vein. The results were ... |
| | | | 11/13/14 | Medtronic Study Reveals Significant Heart Rhythm Disorders Occurring in Patients Undergoing Hemodialysis| Data Presented at Kidney Week 2014 Find Irregular Heartbeats Occur Frequently Around Hemodialysis Sessions MINNEAPOLIS and PHILADELPHIA - Nov. 13, 2014 - Medtronic, Inc. (NYSE: MDT) today revealed the results of a new study which found that atrial fibrillation (AF) and bradycardia-two common heart rhythm disorders-occurred at higher than expected, and clinically significant, rates in patients with end-stage renal disease (ESRD) undergoing hemodialysis. Moreover, these worrisome rhythm disorder... |
| | | | 11/13/14 | HeartWare Presentation At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum To Be Webcast| FRAMINGHAM, Mass., Nov. 13, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity 2014 Medical Technology & Diagnostics Forum at 10:00 a.m. EST on Thursday, November 20, 2014. The one-day conference is being held at the Westin Grand Central, New... |
| | | | 11/13/14 | Form 8.1 – Covidien| DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 13, 2014--
Covidien plc:
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL
ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM
FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
... |
| | | | 11/12/14 | Medtronic Adds to Endurant 'AAA' Stent Graft System| New Bifurcated Component Leverages Proven Design of Predicate Device and Expands Anatomical Customization Options for Endovascular Repair of Abdominal Aortic Aneurysms MINNEAPOLIS -- Nov. 12, 2014 -- The global leader in medical technology for endovascular aortic repair (EVAR), Medtronic, Inc. (NYSE: MDT) today announced the launch in Europe and the United States of the Endurant IIs AAA stent graft, which recently received the CE (Conformité Européene) mark and U.S. Food and Drug Administration ... |
| | | | 11/10/14 | Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2015| MINNEAPOLIS - Nov 10, 2014 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the second quarter of its fiscal year 2015 on Tuesday, November 18, 2014. A news release will be issued at approximately 6:15 a.m. Central Standard Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic's second fiscal quarter which ended October 24, 2014. Medtronic will host a webcast at 7:00 a.m. ... |
| | | | 11/10/14 | Medtronic Announces Japanese Approval and Launch of Implantable Cardioverter-Defibrillator System to Allow for Full-Body MRI Scans| Evera MRI(TM) ICD System Combines Proven Treatment Performance, Increased Longevity and Improved Comfort with Full-Body MRI Access MINNEAPOLIS - Nov. 10, 2014 - Medtronic today announced Japanese regulatory approval and launch of the Evera MRI(TM) SureScan® implantable cardioverter-defibrillator (ICD) System for magnetic resonance imaging (MRI) scans positioned on any region of the body. Reimbursement also was approved by Japan's Ministry of Health, Labor and Welfare (MHLW). The Medtronic Ever... |
| | | | 11/07/14 | HeartWare Presentation At The Credit Suisse 2014 Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., Nov. 7, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Credit Suisse 2014 Healthcare Conference at 2:00 p.m. MST (4:00 pm EST) on Wednesday, November 12, 2014. The conference is being held November 10-13 at the Arizona Biltmore in Phoenix.
... |
| | | | 11/05/14 | Covidien Announces Nine-Month Results of DURABILITY Iliac Study, Addition of Iliac Indication for EverFlex™ Stent System at VIVA 2014| EverFlex™ Self-Expanding Stent System Safe and Effective for the
Treatment of Iliac Stenosis
LAS VEGAS--(BUSINESS WIRE)--Nov. 5, 2014--
Covidien plc (NYSE: COV) today announced nine-month results of the
DURABILITY Iliac study and addition of the iliac indication for its
EverFlex™ stent at the Vascular Interventional Advances (VIVA) 2014
conference. The nine-month results confirm the safety and effectiveness
of the EverFlex™ and Protégé™ GPS™ s... |
| | | | 11/05/14 | New Harvard Business Review Insight Center, Sponsored by Medtronic, Features Online Forum Focused on Innovating for Value in Healthcare| MINNEAPOLIS, Nov. 5, 2014 - Today marks the launch of a new Harvard Business Review (HBR) Insight Center, exclusively sponsored by Medtronic, which provides a forum for thought-leading commentary, editorial content and dialogue focused on innovating for value in healthcare. The Insight Center is a collaboration between HBR and the New England Journal of Medicine (NEJM) and provides an online forum for leaders, managers and others in healthcare. The Insight Center will feature articles from l... |
| | | | 11/05/14 | Covidien Reports Fourth-Quarter and Fiscal 2014 Results| Fourth-quarter net sales up 7%; Medical Devices sales up 8%
Fourth-quarter diluted GAAP earnings per share were $1.13;
excluding specified items, adjusted diluted earnings per share were
$1.15
Fiscal 2014 diluted GAAP earnings per share were $3.65; excluding
specified items, adjusted diluted earnings per share were $4.15, up 12%
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 5, 2014--
Covidien
p... |
| | | | 11/04/14 | Covidien Announces 12-Month DEFINITIVE AR Results at VIVA 2014| Results suggest long-term benefits for peripheral artery disease
patients treated with directional atherectomy followed by a drug-coated
balloon
LAS VEGAS--(BUSINESS WIRE)--Nov. 4, 2014--
Covidien plc (NYSE: COV) today announced 12-month results of the
DEFINITIVE AR study, the first randomized study designed to identify the
clinical benefits of plaque removal using directional
atherectomy followed by drug coated balloon. The results were
... |
| | | | 11/04/14 | Medtronic Drug-Coated Balloon for Peripheral Artery Disease Also Benefits Patients with Diabetes in Landmark Study| Consistent Outcomes Despite Common and Challenging Comorbidity Reinforce Overall Findings of IN.PACT SFA Trial LAS VEGAS -- Nov. 4, 2014 -- For the treatment of peripheral artery disease in leg arteries above the knee, the IN.PACT Admiral drug-coated balloon from Medtronic, Inc. (NYSE: MDT) provided a consistently favorable treatment effect in patients with diabetes in a landmark study of the investigational medical device, which is under review by the U.S. Food and Drug Administration (FDA) fo... |
| | | | 11/04/14 | Covidien’s HawkOne™ Directional Atherectomy System Receives FDA 510(K) Clearance for the Treatment of Peripheral Arterial Disease| The HawkOne™ System strengthens Covidien’s directional atherectomy
platform with a versatile solution for the treatment of peripheral
arterial disease
DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 4, 2014--
Covidien plc (NYSE: COV) today announced U.S. Food and Drug
Administration 510(k) clearance for the HawkOne™ directional atherectomy
system. The latest addition to Covidien’s directional
atherectomy portfolio, the HawkOne™ system provides physic... |
| | | | 11/04/14 | Medtronic of Canada Recognized as One of Canada's Top 100 Employers for 2015 - for the Fifth Year Running| Employee Engagement, Philanthropy Among Top Reasons for Selection BRAMPTON, ONTARIO - November 4, 2014 - Medtronic of Canada Ltd., a trusted Canadian leader in innovative medical technologies and health system solutions, is pleased to have been recognized as one of Canada's Top 100 Employers for 2015, for the fifth year in a row. Medtronic's employee engagement initiatives, philanthropic activities, and a top tier benefits package, are among some of the many reasons Medtronic is considered a t... |
| | | | 11/03/14 | Spectranetics to Acquire Stellarex™ Drug Coated Balloon Assets From Covidien | Conference Call Monday at 8:30 a.m. ET
Expands Spectranetics' portfolio of solutions to treat complex vascular conditions in projected $700 million drug coated balloon segment
COLORADO SPRINGS, Colo., and DUBLIN, Ireland, Nov. 2, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC) and Covidien plc (NYSE:COV) today announced a definitive agreement under which Spectranetics will acquire Covidien's Stellarex™ drug coated angioplasty balloon (DCB) platform for $30 million.
The... |
| | | | 11/03/14 | Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent Following CE Mark| First and Only DES with Novel CoreWire Technology Allows for Thinner, Stronger Struts, Enhanced Deliverability and Radiopacity without Compromising Structural Strength MINNEAPOLIS - Nov. 3, 2014 - Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européene) mark and international launch of the Resolute Onyx(TM) Drug-Eluting Stent (DES). The first live patient implant of the Resolute... |
| | | | 10/30/14 | HeartWare International Reports $68.6 Million In Third Quarter 2014 Revenue; 25% Increase From Third Quarter 2013| - Record 675 HeartWare® Ventricular Assist Systems sold worldwide in Q3
- U.S. revenue of $39.1 million, 39% growth from third quarter 2013
- International revenue of $29.5 million, 11% growth from third quarter 2013
- Conference call today at 8:00 a.m. U.S. EDT -
FRAMINGHAM, Mass., Oct. 30, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of ... |
| | | | 10/28/14 | Medtronic Begins Global Clinical Study of Investigational Pericardial Surgical Aortic Heart Valve| MINNEAPOLIS - October 28, 2014 - Medtronic, Inc. (NYSE: MDT) today announced it has initiated the PERIGON (PERIcardial SurGical AOrtic Valve ReplacemeNt) Pivotal Trial, a global, prospective clinical trial evaluating an investigational surgical aortic heart valve made from bovine pericardial (cow heart) tissue that is intended to replace a diseased, damaged or malfunctioning native or prosthetic aortic valve. The valve was recently implanted in the first U.S. patient at the ProMedica Toledo Hosp... |
| | | | 10/28/14 | Covidien Launches First and Only Articulating Reloadable Absorbable Fixation Device for Minimally-Invasive Hernia Repair| ReliaTack™ device delivers superior access, stronger fixation and
lower cost of care for minimally invasive hernia repair
DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 28, 2014--
Covidien plc (NYSE:COV) today announced the launch of ReliaTack™
articulating reloadable fixation device, the first and only of its kind
for laparoscopic (minimally invasive) hernia repair.‡
ReliaTack™ from Covidien is the first and only articulating reloadable absorbable f... |
| | | | 10/27/14 | Covidien Launches Next-Generation SuperDimension™ Lung Navigation Software to Simplify Planning, Enhance Visualization During a Procedure| Company Delivers Latest Innovation Focused on Aiding in Diagnosis
of Lung Cancer
DUBLIN--(BUSINESS WIRE)--Oct. 27, 2014--
Further underscoring its ongoing commitment to lung health, Covidien
(NYSE:COV) today unveiled a next-generation version of its superDimension™
Navigation System software. The updated software features a more
intuitive interface that helps reduce time spent by physicians planning
the procedure and enhances the visualization... |
| | | | 10/23/14 | Covidien Joins Forces with the American Lung Association to Help Women Understand Their Increased Risk of Lung Cancer| Lung cancer is the number one cancer killer of women
Sponsorship of American Lung Association LUNG FORCE initiative will
help raise lung cancer awareness, change misconceptions
DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 23, 2014--
Covidien (NYSE: COV) is joining forces with the American Lung
Association’s LUNG FORCE movement to raise awareness of the threat that
lung cancer poses to women. As Education Sponsor of LUNG FORCE, the
company is... |
| | | | 10/22/14 | Many Underestimate Stroke, Would Miss Warning Signs Despite High Global Death Rate, Prevalence among Women| Covidien-World Stroke Organization Survey Shows Low Knowledge of Stroke Prevention, Treatment Options
Dublin, Ireland and Geneva – Oct. 22, 2014 – Despite its being the second leading cause of death worldwide, many people still do not recognize the threat stroke poses and the warning signs associated with it, according to a new public opinion study sponsored by Covidien and the World Stroke Organization (WSO).
The survey measured awareness of strokes and stroke prevention among adul... |
| | | | 10/21/14 | Medtronic Launches the Divergence(TM) Anterior Cervical Fusion System| System Offers New Approach to Single-Level ACDF Procedures MEMPHIS, TENN. - October 21, 2014 - Medtronic, Inc. (NYSE: MDT) announced the U.S. launch of the DIVERGENCE(TM) Anterior Cervical Fusion System for the treatment of single-level cervical disc disease today at the 2014 Congress of Neurological Surgeons (CNS) Annual Meeting in Boston. The DIVERGENCE(TM) System represents a new approach to one-level anterior cervical discectomy with fusion (ACDF) procedures, which traditionally... |
| | | | 10/20/14 | Medtronic Announces Global Launch of Titanium-Coated Peek Interbody Fusion Devices| MEMPHIS, TENN., - October 20, 2014 - Medtronic, Inc. (NYSE: MDT) introduced its Pure Titanium Coating (PTC) platform of interbody fusion devices for the spine today at the 2014 Congress of Neurological Surgeons (CNS) Annual Meeting in Boston. The PTC platform includes four products: the CAPSTONE PTC(TM) Spinal System, CLYDESDALE PTC(TM) Spinal System, ANATOMIC PEEK PTC Cervical Fusion System and CORNERSTONE-SR® Ti- Coated Anatomical Cervical Cage. These devices are used to treat patients exper... |
| | | | 10/17/14 | U.S. District Court Grants Covidien Preliminary Injunction against Ethicon’s Harmonic ACE®+7| DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 17, 2014--
Covidien
plc (NYSE: COV) today announced that the U.S. District Court for the
District of Connecticut has granted a preliminary injunction against
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company. This injunction
results from a lawsuit filed by Covidien in June 2014 that alleges
Ethicon’s latest ultrasonic surgical product, the Harmonic ACE®+7,
infringes three Covidien patents. The injun... |
| | | | 10/15/14 | HeartWare Schedules Third Quarter Conference Call And Webcast| FRAMINGHAM, Mass., Oct. 15, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR) has scheduled a conference call to discuss its financial results for the three months ended September 30, 2014, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, October 30, 2014. The Company plans to release the financial results prior to the conference call.
The conference call with management will discuss the Company's financial results, highlights from the third quarter and business outlook. ... |
| | | | 10/14/14 | Medtronic Announces FDA Approval of Pacing Lead for Full-Body MRI Scans| CapSureFix Novus(TM) MRI SureScan ® 5076 Pacing Lead Approved for MR-Conditional Use in Patients with Slow Heartbeat MINNEAPOLIS - October 14, 2014 -- Medtronic today announced the U.S. Food and Drug Administration (FDA) approval of its CapSureFix Novus(TM) MRI SureScan® 5076 Lead for use with magnetic resonance imaging (MRI). The lead is approved for MRI scans positioned on any region of the body when paired with a Medtronic dual-chamber MR-conditional pacemaker. The 5076 lead, previously appro... |
| | | | 10/14/14 | Medtronic Begins Pivotal Study of First Predictive Low Glucose Management Technology for People with Diabetes| In-Clinic Study Marks Critical Step Toward an Artificial Pancreas and Key Milestone Toward U.S. Commercialization MINNEAPOLIS - October 14, 2014 - Medtronic, Inc. (NYSE:MDT) today announced that the first patients have been enrolled in an investigational device exemption (IDE) study of its breakthrough Predictive Low Glucose Management (PLGM) technology, marking a critical step toward development of an artificial pancreas in the U.S. market. The trial will evaluate the safety of its next-genera... |
| | | | 10/13/14 | Covidien Promotes Greater Global Awareness of Thrombosis Risks| Partners with International Society of Thrombosis and H aemostasis to Support World Thrombosis Day Campaign
October 13, 2014 12:01 AM Eastern Daylight Time
DUBLIN, Ireland--(BUSINESS WIRE)--As part of a global effort to highlight the threat posed by venous thromboembolism (VTE), Covidien plc today announced it will support the inaugural World Thrombosis Day campaign as a Global Partner. Developed by the International Society on Thrombosis and Haemostasis (ISTH), the campaign... |
| | | | 10/13/14 | Medtronic CoreValve System Shows Exceptional Outcomes and Valve Performance in TAVI Patients Treated Via Direct Aortic Access| Late-Breaking ADVANCE Direct Aortic Study Presented at EACTS Reaffirms CoreValve System's Positive Performance with Low Mortality and Stroke MINNEAPOLIS and MILAN - Oct. 13, 2014 -Medtronic, Inc. (NYSE: MDT) today announced positive data from nine European centers in a study of the direct aortic approach (through the upper chest) with the CoreValve® System is a safe and effective alternative for aortic stenosis patients at increased risk for surgery who are not suitable for transcatheter aortic... |
| | | | 10/10/14 | Covidien Initiates Voluntary Field Safety Alert for Medi-Trace™ Cadence and Kendall™ Multi-function Defibrillation Electrodes| Dublin, Ireland -- October 10, 2014 – Covidien today announced that it has notified customers of a voluntary Field Safety Alert for certain Medi-Trace™ Cadence and Kendall™ Multi-function Defibrillation Electrodes due to a connector compatibility issue with Philips FR3 and FRx Defibrillators.
These electrodes will not connect with Philips FR3 or FRx AED units, and in the case of the use of Covidien defibrillation electrodes with the Philips FR3 AED units, could result in a delay of thera... |
| | | | 10/10/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – October 10, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 10, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on October 9, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 452,620,558 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Shares ... |
| | | | 10/10/14 | Medtronic Announces Executive Leadership Team for Combined Organization Upon Close of Covidien Acquisition| MINNEAPOLIS -- October 10, 2014 -- Medtronic (NYSE: MDT) today announced the executive team who will lead the combined organization following the close of its proposed acquisition of Covidien. The new company will be comprised of four major business groups and four geographic regions led by a new Executive Committee. Omar Ishrak will remain as chairman and chief executive officer of the new company, Medtronic plc. "The planned acquisition of Covidien will greatly accelerate our joint v... |
| | | | 10/09/14 | Covidien Announces U.S. Food and Drug Administration 510(k) Clearance for Nellcor™ Portable SpO2 Patient Monitoring System| Monitor is only portable oximeter on the market that is indicated for
use in home care settings and is compliant with international standards
for devices used in the home health care environment
DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 9, 2014--
Covidien
plc (NYSE: COV) today announced U.S. Food and Drug Administration
510(k) clearance for the Nellcor™ Portable SpO2 Patient
Monitoring System (PM10N). The system is the only commercially available... |
| | | | 10/08/14 | Form 8.1 – Covidien| DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 8, 2014--
FORM 8.1(a)&(b)(i)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL
ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM
FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
... |
| | | | 10/08/14 | Form 8.1 – Covidien| DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 8, 2014--
Covidien plc:
FORM 8.1(a)&(b)(i)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL
ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM
FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS
1. KEY INFORMATION
... |
| | | | 10/07/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – October 7, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Oct. 7, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on October 6, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 452,488,239 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Shares i... |
| | | | 10/07/14 | New Evaluation System Leads to Incontinence Relief| FDA-Approved System Provides Patients with Added Benefits While Testing Innovative Therapy for Bladder and Bowel Incontinence MINNEAPOLIS - October 7, 2014 - After living with overactive bladder and urinary retention symptoms for 11 years, Jennifer LaForest, a 26-year-old woman from Auburn Hills, Michigan, recently became one of the first in the U.S. to receive a test evaluation with the new Verify(TM) Evaluation System from Medtronic, and subsequently received Medtronic Bladder Control Therap... |
| | | | 10/03/14 | Medtronic Announces Updated Financing Plans for Covidien Acquisition| Company reaffirms commitment to Covidien transactionCompany intends to utilize $16 billion in external debt to finance cash portion of transactionTransaction remains strategically and financially compellingDefinitive agreement terms remain unchanged MINNEAPOLIS -October 3, 2014- Medtronic, Inc. (NYSE: MDT), a global leader in medical technology, services and solutions, today announced that it intends to use approximately $16 billion in external financing to complete the acquisition of Co... |
| | | | 09/30/14 | Survey Shows 43 Percent of Americans Ages 40 and Older Have
Experienced Symptoms of Peripheral Arterial Disease (PAD)| Despite prevalence of PAD symptoms, the majority of patients have
not consulted a physician
DUBLIN, Ireland, Sep 30, 2014 (BUSINESS WIRE) --More than 40 percent of Americans aged 40 and older have experienced one
or more of the most common symptomsi of peripheral arterial
disease (PAD). However, the majority are unfamiliar with the disease and
relatively few who experience symptoms see a doctor, according a recent
online awareness survey conduct... |
| | | | 09/29/14 | Medtronic Extends Title Sponsorship of Twin Cities Marathon Through 2020| Building on Nearly a Decade of Growth, Partnership Allows Twin Cities In Motion to Continue to Expand and Enhance Race Events and Youth Programming MINNEAPOLIS - Sept. 29, 2014 -Medtronic and Twin Cities In Motion, the organizers of the Medtronic Twin Cities Marathon, today announced a five-year, $2.5 million agreement that will keep Medtronic as the title sponsor of the Twin Cities Marathon and three additional Twin Cities In Motion events through 2020: the TC 1 Mile, TC Family Events, and TC ... |
| | | | 09/25/14 | Medtronic Announces $6 Million Philanthropic Effort to Prevent and Control Rheumatic Heart Disease | $6 Million Marks the Largest Private-Sector Contribution to Date to Address One of the World's Most Neglected, Yet Preventable, Diseases Affecting the World's Poor MINNEAPOLIS - September 25, 2014 - Medtronic today announced a five-year, $6 million (USD) funding commitment from Medtronic Philanthropy to reduce premature mortality resulting from Rheumatic Fever (RF) and Rheumatic Heart Disease (RHD). Funding will support projects focused in three countries yet to be determined. The commitment... |
| | | | 09/25/14 | Covidien plc to Report Fourth-Quarter and Fiscal 2014 Results on November 5, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Sep. 25, 2014--
Covidien
plc (NYSE: COV) will report fourth-quarter and fiscal 2014 results on
November 5. The company will host a conference call for investors at
8:30 a.m. ET. The call can be accessed in the following ways:
Via webcast at Covidien’s website: http://investor.covidien.com
By telephone: For both “listen-only” participants and those
participants who wish to take... |
| | | | 09/24/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – September 24, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Sep. 24, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on September 23, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 451,928,666 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Shar... |
| | | | 09/22/14 | Medtronic Announces CE Mark and European Launch of TYRX(TM) Absorbable Antibacterial Envelope| MINNEAPOLIS - Sept. 22, 2014 - Medtronic, Inc. (NYSE: MDT) has received CE (Conformité Européenne) Mark for the TYRX(TM) Absorbable Antibacterial Envelope. This innovative mesh envelope covers an implantable cardiac device to help stabilize the device after implantation and reduce surgical-site infections. The efficacy of the previous generation, non-absorbable TYRX(TM) Antibacterial Envelope* has been shown in three published studies, with new six-month follow-up data from the CITADEL/CENTURI... |
| | | | 09/18/14 | Covidien SonicisionTM Portfolio Expansion Enables Surgeons to Choose Ideal Cordless Ultrasonic Dissection Device for Each Patient and Procedure| Commitment to delivering innovative medical technologies creates most
versatile cordless ultrasonic offering in the industry
DUBLIN, Ireland--(BUSINESS WIRE)--Sep. 18, 2014--
Covidien
plc (NYSE:COV) today announced the expansion of its
Sonicision™ Cordless Ultrasonic Dissection Device portfolio, following
U.S. Food and Drug Administration 510(k) clearance of three additional
device lengths: 13 cm, 26 cm, and 48 cm. With the most versatile
... |
| | | | 09/17/14 | Covidien Announces Dividend Increase| DUBLIN, Ireland--(BUSINESS WIRE)--Sep. 17, 2014--
Covidien
plc (NYSE: COV) today announced that its Board of Directors has
declared a 13% increase in the quarterly dividend rate, from $0.32 per
ordinary share to $0.36 per ordinary share.
“This increase is consistent with our Board’s stated objective of moving
to a higher payout ratio and returning free cash flow to shareholders,”
said José E. Almeida, chairman, president and CEO, Covidien.... |
| | | | 09/17/14 | Medtronic Elects Elizabeth Nabel to the Board of Directors| MINNEAPOLIS - Sept. 17, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that its Board of Directors elected Elizabeth Nabel, M.D., president of Brigham & Women's Hospital and Brigham & Women's Faulkner Hospital, to the Board as an independent director.
Dr. Nabel is a cardiologist and distinguished biomedical researcher and has served as president of Brigham & Women’s hospital since 2010 where she has led the development of an innovative, comprehensive strategic plan that defines ... |
| | | | 09/17/14 | Medtronic Launches New Balloon Kyphoplasty Products for Treating Spinal Fractures| Enhancements Give Physicians More Options for Treating Vertebral Compression Fractures MEMPHIS, TN - September 17, 2014 - Medtronic, Inc. (NYSE: MDT), today announced the launch of the KYPHON Express(TM) II Balloon Kyphoplasty Platform, which includes the next generation KYPHON ® Cement Delivery System. This new platform is the latest advancement in the KYPHON® Balloon Kyphoplasty (BKP) technology for the treatment of vertebral compression fractures. The KYPHON Express(TM) II Balloon Kyphoplasty... |
| | | | 09/16/14 | Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease| IN.PACT Global Study Reports Favorable Outcomes in Real-World Patient Population and Validates Key Findings from IN.PACT SFA Trial WASHINGTON -- Sept. 16, 2014 -- Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon (DCB) from Medtronic, Inc. (NYSE: MDT) augments an already robust body of evidence that continues to drive a reconsideration of the standard of care for p... |
| | | | 09/16/14 | People with Type 2 Diabetes Achieve Greater Satisfaction with Insulin Pumps vs. Multiple Daily Injections| New Data from the OpT2mise Efficacy Studyto be Presented at EASD Annual Meeting VIENNA - September 16, 2014 - Medtronic, Inc. (NYSE:MDT) today announced that new results from the OpT2mise trial are being presented at the European Association for the Study of Diabetes (EASD) 50th Annual Meeting. OpT2mise is the largest global study to compare insulin pump therapy to multiple daily insulin injections in people with type 2 diabetes with poor glycemic control. Three new poster presentations at EAS... |
| | | | 09/15/14 | Covidien Announces Start of Enrollment in Two Neurovascular Clinical Trials| DUBLIN, Ireland--(BUSINESS WIRE)--Sep. 15, 2014--
Covidien
plc announced today the start of enrollment in two clinical trials
designed to further underscore the safety and effectiveness of the
company’s advanced neurovascular solutions.
Baptist
Medical Center in Jacksonville, Florida, treated the first patient
enrolled in the PREMIER Prospective study, an international
Investigational Device Exemption (IDE) clinical study to evaluat... |
| | | | 09/15/14 | Medtronic Launches SEEQ(TM) Wearable Cardiac Monitoring System in United States| New External Heart Monitor and Remote Monitoring Center Help Patients Find Answers to Unexplained Cardiac Symptoms MINNEAPOLIS - September 15, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. launch of the SEEQ(TM) Mobile Cardiac Telemetry (MCT) System, an external, wire-free, adhesive heart monitor that can be worn for up to 30 days to help detect and diagnose the cause of irregular heartbeats in patients. Medtronic completed the acquisition of U.S.-based Corventis, Inc., which deve... |
| | | | 09/13/14 | Medtronic CoreValve System Sustains Positive Outcomes Through Two Years in Extreme Risk Patients| TCT Late-Breaking First Report Reveals High Survival, Low Stroke Rates and Sustained Valve Performance WASHINGTON, D.C. and MINNEAPOLIS - Sept. 13, 2014 - Medtronic, Inc. (NYSE: MDT) today announced new data showing that transcatheter aortic valve replacement (TAVR) with the CoreValve® System continued to provide safe and effective treatment, while maintaining exceptional rates of survival out to two years for patients who were considered too ill or frail to have their aortic valves replaced t... |
| | | | 09/13/14 | Medtronic CoreValve Data Demonstrate Favorable Cost Effectiveness Compared to Open-Heart Surgery in High Risk Patients| Cost Effectiveness of Self-Expanding Valve Driven by Improved Quality of Life Benefit and Superior One-Year Survival Rates over Surgical Aortic Valve Replacement WASHINGTON, D.C., and MINNEAPOLIS - Sept. 13, 2014 - In the first-ever in-trial cost effectiveness analysis of transcatheter aortic valve replacement (TAVR) for patients at high risk for surgery, investigators today revealed new data demonstrating the cost effectiveness of the CoreValve® System from Medtronic, Inc. (NYSE: MDT) for h... |
| | | | 09/11/14 | Medtronic Named One of the World's Leading Companies for Sustainability| MINNEAPOLIS - Sept. 11, 2014 - Medtronic, Inc. (NYSE: MDT) was recognized as one of the world's leading companies for sustainability with its ranking on the Dow Jones Sustainability World Index (DJSI World) for the fourth year in a row. DJSI World analyzes companies on a variety of sustainability criteria, including economic performance, environmental stewardship and social responsibility. This adds to the recognition Medtronic received earlier this year through its continued inclusion in the F... |
| | | | 09/11/14 | Medtronic NC Euphora(TM) Coronary Balloon Receives FDA Clearance| Superior Deliverabilityi and Uncompromising Performance Distinguishes New Angioplasty Balloon New "Cath Lab Connect" Website Will Provide Catheter Lab Professionals with Educational Resources and Best Practice Sharing Platform MINNEAPOLIS -- Sept. 11, 2014 -- Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of the NC Euphora(TM) Noncompliant Balloon Dilatation Catheter. The new device will be featured for the first t... |
| | | | 09/10/14 | Medtronic Announces First U.S. Implants in Clinical Study of Recapturable CoreValve Evolut R| First Patients Successfully Treated in Study to Evaluate Next Generation Transcatheter Valve MINNEAPOLIS - Sept. 10, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the first U.S. implants in the CoreValve Evolut R Clinical Study, which will evaluate the safety and effectiveness of the new Medtronic CoreValve®Evolut(TM) R System. This novel investigational self-expanding valve and 14FR equivalent delivery system offer new capabilities that are designed to advance deliverability and valve p... |
| | | | 09/03/14 | Medtronic Announces CE Mark for Recapturable CoreValve Evolut R System | Next-Generation TAVI System Offers Ability to Recapture and Reposition During Deployment MINNEAPOLIS - Sept. 3, 2014 - Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européene) Mark for the 23 mm CoreValve® Evolut(TM) R System for transcatheter aortic valve implantation (TAVI). The novel, self-expanding valve and 14FR equivalent delivery system offers new capabilities that advance valve performance and deliverability during the procedure, while providing the option to recapture (r... |
| | | | 09/02/14 | Medtronic CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference| MINNEAPOLIS - Sept 2, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Morgan Stanley Global Healthcare Conference, September 8, 2014, in New York. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 3:25 p.m. EDT (2:25 p.m. CDT). A live audio webcast of the presentation will be available on September 8, 2014, by clicking on the Invest... |
| | | | 08/28/14 | Medtronic Receives Clearance for the SHILLA(TM) Growth Guidance System| First U.S. Growth Guidance System Cleared to Treat Scoliosis with Children's Needs in Mind MEMPHIS, TN - Aug. 28, 2014 - Medtronic, Inc. (NYSE: MDT), today announced the 510(k) clearance and launch of the SHILLA(TM) Growth Guidance System. The system is designed for treatment of skeletally immature pediatric patients less than 10 years of age diagnosed with severe, progressive, life-threatening, early-onset spinal deformities. The SHILLA(TM) Growth Guidance System is a new growth-sparing tech... |
| | | | 08/28/14 | Covidien Acquires Venous Disease Treatment Developer Sapheon, Inc.| Transaction expands Covidien’s market leading portfolio with next
generation technology for treatment of varicose veins
DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 28, 2014--
Covidien
plc (NYSE: COV) today announced that it has acquired Sapheon,
Inc., a privately-held developer of venous disease treatments.
Financial terms of the transaction were not disclosed.
Based in Morrisville, N.C., Sapheon develops and manufactures the
VenaSea... |
| | | | 08/27/14 | Medtronic Announces First Implants in Largest-Ever, Global Trial of Cardiac Resynchronization Therapy| Post-Market Clinical Trial Will Assess Superiority of the AdaptivCRT® Feature Compared to Standard CRT MINNEAPOLIS - Aug. 27, 2014 - Medtronic, Inc. (NYSE:MDT) today announced the first implants in a clinical trial that will compare patient and healthcare system outcomes - including patient mortality and hospitalizations - in heart failure patients who have cardiac resynchronization therapy (CRT) devices with the AdaptivCRT® feature enabled versus patients receiving standard CRT. The AdaptRespo... |
| | | | 08/27/14 | Medtronic Acquires NGC Medical to Strengthen Its Integrated Health Solutions Portfolio| NGC's Hospital Managed Services Business Adds to Medtronic's Growing Healthcare Services and Solutions Portfolio TOLOCHENAZ - August 27, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has completed the acquisition of NGC Medical S.p.A. (NGC), a privately-held Italian company, in a transaction that values NGC at $350 million. Medtronic held a 30 percent ownership stake in the company prior to the completion of the acquisition. NGC will serve as the Managed Services arm for Medtronic'... |
| | | | 08/26/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – August 26, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 26, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on August 25, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 451,825,023 ordinary shares, par
value US$0.20 per share (the “Ordinary Shares”). The
International Securities Identification Number (ISIN) of the Ordinary
Shares ... |
| | | | 08/26/14 | Medtronic Acquires Sapiens Steering Brain Stimulation| Sapiens' Deep Brain Stimulation Technologies Strengthen Medtronic's Neuromodulation Portfolio and Neuroscience Leadership Position MINNEAPOLIS and EINDHOVEN - Aug. 26, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has acquired Sapiens Steering Brain Stimulation (Sapiens SBS), a privately held developer of deep brain stimulation (DBS) technologies for approximately $200 million in an all-cash transaction. The acquisition of Sapiens SBS strengthens Medtronic's capabilities in an impor... |
| | | | 08/25/14 | Medtronic Viva® Cardiac Resynchronization Therapy-Pacemaker Now Available in U.S.| AdaptivCRT® Algorithm Customizes Therapy for Heart Failure Patients and Improves Their Response Rates MINNEAPOLIS - Aug. 25, 2014 - Medtronic, Inc. (NYSE:MDT) today announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P, for indicated patients with heart failure or atrioventricular (AV) block. The Viva CRT-P includes the Medtronic-exclusive AdaptivCRT® algorithm, which preserves normal heart rhythms and automatically ... |
| | | | 08/22/14 | Covidien Acquires Reverse Medical Corporation| Generates Opportunity to Leverage Existing Vascular Technologies and
Customer Relationships to Drive Increased Market Penetration
DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 22, 2014--
Covidien
plc (NYSE:COV) today announced it has acquired Reverse
Medical Corporation, a privately held
medical device company focused on expanding the management of vascular
disease. Financial terms of the transaction were not disclosed.
“Covid... |
| | | | 08/21/14 | Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2015| MINNEAPOLIS - August 21, 2014 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.305 per share of the company's common stock. The quarterly dividend represents a 9 percent increase over the prior year. The dividend is payable on October 24, 2014, to shareholders of record at the close of business on October 3, 2014. Medtronic, a constituent of the S&P 500 Dividend Aristocrats index, has committed to returning 50 percent of its free cash flow to shareholde... |
| | | | 08/21/14 | FDA Approves Changes to Manufacturing Process for Covidien’s Pipeline™ Embolization Device| DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 21, 2014--
Covidien
plc (NYSE: COV) today announced that the U.S. Food and Drug
Administration (FDA) has approved changes to the manufacturing process
for the polytetrafluoroethylene (PTFE) coating on the delivery wire of
the company’s Pipeline™ embolization device.
On April 1, 2014, Covidien voluntarily recalled certain lots of Pipeline
and Alligator™ retrieval devices on which the PTFE coating app... |
| | | | 08/20/14 | Covidien Opens Advanced Medical Technology Center in Brazil| Facility offers educational resources, research capabilities
SÃO PAULO--(BUSINESS WIRE)--Aug. 20, 2014--
Covidien
plc (NYSE: COV) today officially opened its Covidien Center of
Innovation Brazil (CCI Brazil), further expanding its educational and
research capabilities in a key emerging market. The CCI will help
educate clinicians in Brazil and the surrounding region on the latest
medical technology, enabling them to more safely and efficiently... |
| | | | 08/20/14 | Greater Twin Cities United Way and Medtronic Join Forces to Advance Health Equity in Minnesota| MINNEAPOLIS - August 20, 2014 - Greater Twin Cities United Way today strengthened their long-standing commitment to improving the health and well-being of Twin Cities' communities by teaming up with Medtronic Philanthropy on a new partnership designed to promote access to quality healthcare in the region. This commitment is a five-year, $2.5-million initiative that will leverage shared research, resources and community-based approaches to give people in underserved communities a better chance to... |
| | | | 08/19/14 | Medtronic Reports First Quarter Earnings| Revenue of $4.3 Billion Grew 4% on Constant Currency Basis; 5% as Reported Non-GAAP Diluted EPS of $0.93, Growth of 6%; GAAP Diluted EPS of $0.87, Decline of 6% Company Reiterates FY15 Revenue Growth Outlook and EPS Guidance Company Reaffirms Commitment to Covidien Transaction MINNEAPOLIS - Aug. 19, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its first quarter of fiscal year 2015, which ended July 25, 2014. The company reported worldwide first quarter revenu... |
| | | | 08/18/14 | Study Published in JACC CI Demonstrates Directional Atherectomy Effective as Frontline Therapy for Peripheral Arterial Disease Patients| Largest directional atherectomy study with independent, core lab
analysis demonstrates high limb salvage in patients with critical limb
ischemia and strong patency rates in both diabetic and claudicant
patients
DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 18, 2014--
Directional atherectomy is safe and effective as a frontline therapy for
the treatment of peripheral arterial disease (PAD), according to a
landmark Covidien study published online today... |
| | | | 08/11/14 | Medtronic to Announce Financial Results for its First Quarter of Fiscal Year 2015| MINNEAPOLIS - Aug. 11, 2014 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the first quarter of its fiscal year 2015 on Tuesday, August 19, 2014. A news release will be issued at approximately 6:15 a.m. Central Daylight Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic's first fiscal quarter which ended July 25, 2014. Medtronic will host a webcast at 7:00 a.m. Centra... |
| | | | 08/11/14 | Medtronic Announces 2014 "Global Heroes" Team| Distance Runners from Around the World Who Benefit from Medical Technology to Run Medtronic Twin Cities Marathon Events this Fall MINNEAPOLIS - August 11, 2014 - Twenty-five long-distance runners who benefit from medical technology will be honored as "Medtronic Global Heroes" when they run as a team in the Medtronic Twin Cities Marathon or TC 10 Mile on Sunday, October 5, 2014. This year's team includes runners from 10 different countries: Australia, Brazil, Canada, China, Colombia... |
| | | | 08/07/14 | Medtronic Receives FDA Approval for Attain Performa® Quadripolar Lead and Viva® Quad CRT-Ds in United States| New System Helps Physicians Deliver Cardiac Resynchronization Therapy Optimally and Efficiently to Heart Failure Patients MINNEAPOLIS - Aug. 7, 2014 - Medtronic, Inc. (NYSE: MDT) today announced it has received United States Food and Drug Administration (FDA) approval for the Attain Performa® Model 4298 quadripolar lead, and the Viva® Quad XT and Viva® Quad S cardiac resynchronization therapy defibrillators (CRT-D). The quadripolar lead and devices will be broadly available to physicians in mi... |
| | | | 08/05/14 | HeartWare Presentation At The Canaccord Genuity 34th Annual Growth Conference To Be Webcast| FRAMINGHAM, Mass., Aug. 5, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity 34th Annual Growth Conference at 9:00 a.m. EDT on Thursday, August 14, 2014. The conference is being held August 13-14 at the InterContinental Boston.
A live webcast... |
| | | | 08/04/14 | HeartWare International Announces Appointment Of Katrin Leadley, M.D., As Chief Medical Officer| FRAMINGHAM, Mass., Aug. 4, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced the appointment of Katrin Leadley, M.D., as Chief Medical Officer of HeartWare, effective September 1, 2014. Leadley brings to HeartWare extensive strategic leadership, with more than 20 years of clinical and industry experience at life sc... |
| | | | 08/01/14 | Medtronic Launches NuVent(TM) EM Sinus Dilation System for Fusion® ENT Navigation System| System Offers Innovative Technology for Sinus Surgery. Chronic Sinusitis Affects Nearly 29 Million US Adults MINNEAPOLIS - August 1, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the launch of the NuVent(TM) EM Sinus Dilation System for the Fusion® ENT Navigation System, developed and manufactured by the company's Ear Nose and Throat (ENT) division of its Surgical Technologies business. NuVent is the first and only balloon sinus dilation system with built-in electromagnetic (EM) surgical n... |
| | | | 07/31/14 | HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013| - Record 674 HeartWare® Ventricular Assist Systems sold worldwide in Q2
- U.S. revenue of $36.9 million, 47% growth from second quarter 2013
- International revenue of $33.2 million, 29% growth from second quarter 2013
- Conference call today at 8:00 a.m. U.S. EDT -
FRAMINGHAM, Mass., July 31, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment o... |
| | | | 07/28/14 | Medtronic Receives FDA Approval for PRESTIGE® LP Cervical Disc System| The PRESTIGE® LP Cervical Disc is Medtronic's Third Clinically-Proven Artificial Cervical Disc to Receive FDA Approval MEMPHIS, TENN. - July 28, 2014 - Medtronic, Inc. (NYSE: MDT) announces that it has received approval from the U.S. Food and Drug Administration (FDA) to market the PRESTIGE® LP Cervical Disc System for the treatment of single-level cervical disc disease (radiculopathy and/or myelopathy). The PRESTIGE® LP Cervical Disc is the third clinically proven artificial cervic... |
| | | | 07/28/14 | Medtronic Completes Acquisition of Visualase, Inc.| MRI-Guided Laser Ablation Technology Adds to Surgical Technologies Product Portfolio and Broader Neuroscience Leadership Position MINNEAPOLIS - July 28, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has completed the acquisition of Visualase, Inc., a privately held company based in Houston, TX, that develops and markets an FDA-approved MRI-guided laser and image guided system for minimally invasive neurosurgeries, including surgical thermal ablation. Medtronic will add Visualase'... |
| | | | 07/25/14 | Covidien Reports Third-Quarter Fiscal 2014 Results| Net sales up 4%; Medical Devices sales up 5%
Third-quarter diluted GAAP earnings per share were $0.67; excluding
specified items, adjusted diluted earnings per share were $1.04, up 14%
DUBLIN, Ireland--(BUSINESS WIRE)--Jul. 25, 2014--
Covidien
plc (NYSE: COV) today announced financial results for the third quarter
of fiscal 2014. Third-quarter net sales of $2.69 billion increased 4%,
both on a reported and on an ope... |
| | | | 07/22/14 | Covidien Announces Leadership Appointment| DUBLIN, Ireland--(BUSINESS WIRE)--Jul. 22, 2014--
Covidien
plc (NYSE: COV) today announced that Bryan Hanson, who currently
serves as group president, Medical Devices & U.S., will be elevated to
the newly created position of group president, Covidien, effective Oct.
1. In this role, Hanson will have global responsibility for all Covidien
business segments.
Hanson has overseen the company’s Surgical Solutions, Vascular Therapies
and ... |
| | | | 07/17/14 | HeartWare Schedules Second Quarter Conference Call And Webcast| FRAMINGHAM, Mass., July 17, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended June 30, 2014, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, July 31, 2014. The Company plans to release the financial results prior to the conference call.
The conference call with management will discuss the Company's financial results, highlights from the second quarter and business outlook. The cal... |
| | | | 07/16/14 | Covidien Declares Quarterly Cash Dividend| DUBLIN, Ireland--(BUSINESS WIRE)--Jul. 16, 2014--
Covidien
plc (NYSE: COV) today announced that its Board of Directors has
declared a quarterly cash dividend of $0.32 per ordinary share. The
dividend is payable on August 19, 2014, to shareholders of record on
July 29, 2014.
About Covidien
Covidien is a global health care leader that understands the challenges
faced by providers and their patients and works to address them wi... |
| | | | 07/16/14 | Covidien Makes Liver Tumor Ablation More Predictable| Emprint™ Ablation System enables more certainty regardless of target
location or tissue type
DUBLIN, Ireland--(BUSINESS WIRE)--Jul. 16, 2014--
Overcoming a significant roadblock to predictable ablation of soft
tissue, Covidien
plc (NYSE:COV) has unveiled an advanced ablation system that offers
physicians predictable results regardless of the target location or
tissue type. The Emprint™ Ablation System with Thermosphere™ Technology
is de... |
| | | | 07/14/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – July 14, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Jul. 14, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on July 11, 2014, the Company’s issued share capital, excluding
treasury shares, consisted of 451,716,767 ordinary shares, par value
US$0.20 per share (the “Ordinary Shares”). The International
Securities Identification Number (ISIN) of the Ordinary Shares is
... |
| | | | 07/10/14 | Covidien Launches EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System in Australia and New Zealand | Stent Delivery System Offers Controlled, One-Handed Delivery, Greater Accuracy and Ease of Use
DUBLIN, Ireland--(BUSINESS WIRE)-- Covidien plc today announced the launch of its EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System in Australia and New Zealand. The latest version of the EverFlex stent features the new Entrust Delivery System, which enables physicians to consistently place stents with accuracy, while providing the ease of a one-handed device.
“The design of th... |
| | | | 07/08/14 | Covidien Launches Next-Generation Trellis™ Peripheral Infusion System| Treatment for Deep Vein Thrombosis Re designed to Improve Thrombus Isolation, Lytic Drug Delivery, Removal of Blood Clot
BOSTON-- (BUSINESS WIRE)--Covidien today announced the commercial launch of its next generation TrellisTM peripheral infusion system. The redesigned system continues to be the only pharmacomechanical thrombolysis device that enables focused treatment of blood clots that lead to Post-thrombotic Syndrome (PTS). This latest Trellis system has been optimized t... |
| | | | 07/02/14 | People with Type 2 Diabetes Achieve Superior Outcomes with Insulin Pumps vs. Multiple Daily Injections| Comparative Efficacy Results from the OpT2mise Trial Published in The Lancet Could Redefine Management of Insulin-Requiring Type 2 Diabetes MINNEAPOLIS - July 2, 2014 - As an example of its commitment to improving clinical outcomes for all people with diabetes, Medtronic, Inc. (NYSE:MDT) today announced the results of the OpT2mise trial, which showed that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections... |
| | | | 07/02/14 | Form 8.1 – Covidien| DUBLIN, Ireland--(BUSINESS WIRE)--FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TA KEOVER RULES, 2013 DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION Name of person dealing (Note 1) Jose E Almeida Company dealt in ... |
| | | | 07/02/14 | Form 8.1 – Covidien| DUBLIN, Ireland--(BUSINESS WIRE)--FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TA KEOVER RULES, 2013 DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION Name of person dealing (Note 1) Covidien plc Company dealt in ... |
| | | | 06/30/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – June 30, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Jun. 30, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE:COV) (the “Company”) confirms that, as of the close of
business on June 27, 2014, the Company’s issued share capital, excluding
treasury shares, consisted of 451,590,366 ordinary shares, par value
US$0.20 per share (the “Ordinary Shares”). The International
Securities Identification Number (ISIN) of the Ordinary Shares is
... |
| | | | 06/26/14 | Covidien plc to Report Third-Quarter Fiscal 2014 Results on July 25, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Jun. 26, 2014--
Covidien
plc (NYSE: COV) will report third-quarter fiscal 2014 results on July
25. The company will host a conference call for investors at 8:30 a.m.
ET. The call can be accessed in the following ways:
Via webcast at Covidien’s website: http://investor.covidien.com
By telephone: For both “listen-only” participants and those
participants who wish to take part in... |
| | | | 06/25/14 | Study Published in The New England Journal of Medicine Finds Medtronic Insertable Cardiac Monitors Detect Atrial Fibrillation in Stroke Patients Better Than Standard Care| MINNEAPOLIS - June 25, 2014 - Medtronic, Inc. (NYSE: MDT), today announced results from the CRYSTAL AF (CRYptogenic STroke And underLying Atrial Fibrillation) Clinical Trial have been published in The New England Journal of Medicine. The Trial found that continuous cardiac monitoring with the Reveal® XT Insertable Cardiac Monitor (ICM) was superior to standard care at detecting atrial fibrillation (AF) in patients who have had strokes of undetermined causes (cryptogenic stroke). The global study... |
| | | | 06/24/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue – June 24, 2014| DUBLIN--(BUSINESS WIRE)--Jun. 24, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on June 23, 2014, the Company’s issued share capital, excluding
treasury shares, consisted of 451,486,007 ordinary shares, par value
US$0.20 per share (the “Ordinary Shares”). The International
Securities Identification Number (ISIN) of the Ordinary Shares is
IE00B68S... |
| | | | 06/24/14 | Covidien Files Patent Infringement Lawsuit over Ethicon's Ultrasonic Surgical Devices| DUBLIN, Ireland--(BUSINESS WIRE)--Jun. 24, 2014--
Covidien
(NYSE: COV) today announced that it filed a lawsuit in the U.S. District
Court for the District of Connecticut against Ethicon Endo-Surgery,
Inc., a Johnson & Johnson company. The lawsuit alleges that Ethicon’s
latest ultrasonic surgical product, the Harmonic ACE®+7, infringes three
Covidien patents. The same federal court found that these patents were
valid and had been infringed in an ea... |
| | | | 06/24/14 | Covidien Announces European Launch of Pipeline™ Flex Embolization Device| Minimally-invasive flow diversion device for unruptured brain
aneurysms designed for more accurate, controlled placement1
DUBLIN, Ireland--(BUSINESS WIRE)--Jun. 24, 2014--
Further strengthening its broad line of neurovascular products to treat
unruptured brain aneurysms, Covidien
plc (NYSE:COV) announced the European launch of its Pipeline™
Flex embolization device at the annual Live Interventional
Neuroradiology & Neurosurgery Course (LINNC),... |
| | | | 06/20/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue| DUBLIN--(BUSINESS WIRE)--Jun. 20, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc (NYSE: COV) (the
“Company”) confirms that, as of the close of business on
June 19, 2014, the Company’s issued share capital,
excluding treasury shares, consisted of 451,384,813 ordinary shares, par value
US$0.20 per share (the “Ordinary
Shares”). The International Securities Identification Number (ISIN) of
the Ordinary Shares is IE00B68SQD29. The Company confirms
that, ... |
| | | | 06/19/14 | Medtronic Announces Preliminary Outcomes for World's Smallest Cardiac Pacemaker| Results Presented at Cardiostim 2014 MINNEAPOLIS and NICE, France - June 19, 2014 - Medtronic, Inc. (NYSE: MDT) today announced preliminary results from the first human implants of the world's smallest pacemaker, the Micra(TM) Transcatheter Pacing System (TPS). Results from the first four patients to receive the Micra TPS were reported at CARDIOSTIM / EHRA EUROPACE 2014, World Congress in Electrophysiology and Cardiac Techniques, in Nice, France. At 1 month and 3 months, results showed the Mic... |
| | | | 06/18/14 | Study Shows CRT-D Devices with Medtronic AdaptivCRT(TM) Associated with Reduction of Costs of Atrial Fibrillation| Study Supplements Earlier Data Showing Reduction in Hospital Readmissions for Heart Failure Patients with AdaptivCRT Technology MINNEAPOLIS, USA and NICE, FRANCE - June 18, 2014 - New data from the Medtronic, Inc. (NYSE: MDT) Adaptive CRT trial show a 61 percent (p=0.01) lower risk of atrial fibrillation (AF)-related problems in patients who receive a cardiac resynchronization therapy-defibrillator (CRT-D) with the Medtronic-exclusive AdaptivCRT(TM) algorithm compared to conventional biventricu... |
| | | | 06/17/14 | Medtronic Launches $17-Million Program to Improve Heart Disease, Diabetes Care for Underserved Populations| HealthRise Program Supports Localized Healthcare Access Projects in Four Countries as Part of Global Effort to Lessen the Burden of Chronic, Non-Communicable Diseases (NCDs) MINNEAPOLIS - June 17, 2014 - Medtronic today announced the launch of HealthRise, a five-year, $17-million (USD) Medtronic Philanthropy program that supports community-based demonstration projects specifically designed to expand access to care and management of chronic, non-communicable diseases (NCDs) such as heart disease... |
| | | | 06/16/14 | Announcement under Irish Takeover Rules Relevant Securities in Issue| DUBLIN--(BUSINESS WIRE)--Jun. 20, 2014--
In accordance with Rule 2.10 of the Irish Takeover Rules, Covidien plc
(NYSE: COV) (the “Company”) confirms that, as of the close of
business on June 19, 2014, the Company’s issued share capital, excluding
treasury shares, consisted of 451,384,813 ordinary shares, par value
US$0.20 per share (the “Ordinary Shares”). The International
Securities Identification Number (ISIN) of the Ordinary Shares is
IE00B68S... |
| | | | 06/16/14 | Medtronic Increases Its Cash Dividend By Nine Percent| Commitment Remains to Return 50 Percent of Free Cash Flow to Shareholders MINNEAPOLIS - June 16, 2014 - The board of directors of Medtronic, Inc. (NYSE: MDT) approved yesterday a 9 percent increase in its cash dividend, raising the quarterly amount to $0.305 per share of the company's common stock, which would result in an annual amount of $1.22 per share. This dividend increase brings the company's current dividend yield to 2 percent and expected fiscal year 2015 dividend payout ratio to appr... |
| | | | 06/15/14 | Medtronic to Acquire Covidien for $42.9 billion in Cash and Stock| Creates a Medical Technology and Services Company with a Comprehensive Product Portfolio and Broad Global Reach that is Better Able to Improve Healthcare Outcomes Meaningfully Accelerates Medtronic's Core Strategies of Therapy Innovation, Globalization and Economic Value Combined Revenue of $27 Billion, including $3.7 Billion from Emerging Markets Transaction Expected to be Accretive to Medtronic Cash Earnings in FY2016 and Significantly Accretive thereafter Medtronic Commits to $10 Billio... |
| | | | 06/15/14 | Medtronic to Acquire Covidien for $42.9 billion in Cash and Stock| Creates a Medical Technology and Services
Company with a Comprehensive Product Portfolio and Broad Global Reach that is
Better Able to Improve Healthcare Outcomes Meaningfully Accelerates Medtronic’s Core Strategies
of Therapy Innovation, Globalization and Economic Value
Combined Revenue of $27 Billion, including $3.7
Billion from Emerging Markets Transaction Expected to be Accretive to Medtronic Cash
Earnings in FY2016 and Significantly Accretive thereafter
Medtronic Commits to $1... |
| | | | 06/14/14 | Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes| Initial Focus on Insulin-Device Combinations and Care Management Services PARIS, FRANCE, AND MINNEAPOLIS, MN - June 14, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and Medtronic, Inc. (NYSE: MDT) today announced that they have signed a memorandum of understanding to enter into a global strategic alliance in diabetes, aimed at improving patient experience and outcomes for people with diabetes around the world. The alliance will initially focus on two key priorities: the development of drug-devic... |
| | | | 06/12/14 | Medtronic CoreValve® System Receives FDA Approval for Patients at High Risk for Surgery| Accelerated Approval Obtained after Clinical Outcomes with Self-Expanding Valve Prove Superior to Surgical Aortic Valve Replacement at One Year CoreValve System Now Available to More U.S. Patients than any Other Transcatheter Aortic Valve MINNEAPOLIS - June 12, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the self-expanding transcatheter CoreValve® System for patients with severe aortic stenosis who are at high risk for surger... |
| | | | 06/12/14 | HeartWare Presentation at the 2014 Wells Fargo Healthcare Conference to Be Webcast| FRAMINGHAM, Mass., June 12, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2014 Wells Fargo Healthcare Conference at 4:40 p.m. EDT on Tuesday, June 17, 2014. The conference is being held June 17-18 at the InterContinental Boston.
A live webcast of the Compa... |
| | | | 06/11/14 | Medtronic Announces Date for 2014 Annual Meeting| Shareholders Invited to Attend Annual Meeting on Aug. 21, 2014 MINNEAPOLIS - June 11, 2014 - The board of directors of Medtronic, Inc. (NYSE: MDT), announced that the company's annual meeting of shareholders will be held at 10:30 a.m. CDT on Thursday, Aug. 21, 2014 at Medtronic's Mounds View campus, located at 8200 Coral Sea Street N.E., Mounds View, Minnesota. Shareholders of record at the close of business on June 23, 2014, will be eligible to vote at the meeting. About MedtronicMedtronic, ... |
| | | | 06/11/14 | Medtronic Submits Final Data to FDA for Novel Device to Treat Peripheral Artery Disease| Global Leader Projects Introduction of IN.PACT Admiral Drug-coated Balloon to U.S. Market in Early FY16 MINNEAPOLIS - Date - Moving toward U.S. market introduction of its novel medical device to treat peripheral artery disease, Medtronic, Inc. (NYSE: MDT) today announced that it recently submitted the final module of its pre-market approval (PMA) application for the IN.PACT Admiral drug-coated balloon to the U.S. Food and Drug Administration (FDA). The application includes data that demonstra... |
| | | | 06/10/14 | Covidien Neurovascular Micro Catheter Receives FDA Approval| Apollo™ Onyx™ Delivery Micro Catheter with Detachable Tip Enhances
Onyx™ Liquid Embolic System (LES) Delivery
DUBLIN, Ireland--(BUSINESS WIRE)--Jun. 10, 2014--
Covidien
plc (NYSE: COV) today announced U.S. Food and Drug Administration
(FDA) approval of its Apollo™ Onyx™ delivery micro catheter - the
first detachable tip micro catheter available in the U.S. The new micro
catheter is designed to mitigate the technical challenges of catheter
... |
| | | | 06/10/14 | Medtronic CFO Gary Ellis to Speak at Wells Fargo Healthcare Conference| MINNEAPOLIS - June 10, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Wells Fargo Healthcare Conference on Tuesday, June 17, 2014, in Boston. Gary Ellis, executive vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 2:20 p.m. EDT (1:20 p.m. CDT). A live audio webcast of the presentation will be available on June 17, 2014, by clicking on the Investors link... |
| | | | 06/06/14 | HeartWare Presentation At The Goldman Sachs 35th Annual Global Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., June 6, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Goldman Sachs 35th Annual Global Healthcare Conference at 10:00 a.m. PDT (1:00 p.m. EDT) on Thursday, June 12, 2014. The conference is being held June 10-12 at the Terranea Resort in Ran... |
| | | | 06/05/14 | Medtronic Outlines Future Growth Opportunities at Investor Conference| MINNEAPOLIS -- Jun. 5, 2014 -- Medtronic, Inc. (NYSE: MDT) shared during its Investor Conference today in New York City an overview of the state of its business and strategies for future growth opportunities. Chairman and CEO Omar Ishrak emphasized the opportunity that exists to address universal healthcare needs: improving clinical outcomes, expanding access, and optimizing cost and efficiency. He also emphasized the company's integrated health solutions offerings and focus on improving operat... |
| | | | 06/04/14 | Medtronic Expands Availability of Market-Leading Aortic & Peripheral Solutions to U.S. Market| Recently FDA Approved Valiant Captivia Proximal FreeFlo Tapers for Dissection and TOTAL Across Crossing Support Catheter Featured at the 2014 Vascular Annual Meeting MINNEAPOLIS -- Jun. 4, 2014 -- Continuing to expand its market-leading portfolio of endovascular solutions, Medtronic, Inc. (NYSE: MDT) announced today that two recently Food and Drug Administration (FDA) approved devices will be featured at the Society for Vascular Surgery's 2014 Vascular Annual Meeting, taking place June 5-7 in B... |
| | | | 06/04/14 | HeartWare International Comments On FDA Warning Letter| FRAMINGHAM, Mass., June 4, 2014 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR) announced that on June 3, 2014 it received a warning letter from the U.S. Food and Drug Administration (FDA) resulting from an inspection of the company's operations, development and manufacturing facility in Miami Lakes, Florida, conducted in January 2014.
The FDA letter cites four categories for the company to address: procedures for validating device design, including device labeling; procedures fo... |
| | | | 06/03/14 | HeartWare Presentation At The William Blair & Company 34th Annual Growth Stock Conference To Be Webcast| FRAMINGHAM, Mass., June 3, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the William Blair & Company 34th Annual Growth Stock Conference at 4:10 p.m. CDT (5:10 p.m. EDT) on Tuesday, June 10, 2014. The conference is being held June 10-12 at the Four Seasons H... |
| | | | 06/03/14 | Medtronic CEO Omar Ishrak to Speak at Goldman Sachs Global Conference| MINNEAPOLIS - June 3, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 35th annual Goldman Sachs Global Healthcare Conference on Tuesday, June 10, 2014, in Rancho Palos Verdes, CA. Omar Ishrak, chairman and chief executive officer of Medtronic will make a presentation about Medtronic beginning at 3:20 p.m. PDT (5:20 p.m. CDT). A live audio webcast of the presentation will be available on June 10, 2014, by clicking o... |
| | | | 06/03/14 | Medtronic Begins Initial European Market Launch of World's First Combined Glucose Sensor and Insulin Infusion Set for People with Diabetes| MiniMed® Duo(TM) Enhances Simplicity and Comfort of Sensor Augmented Insulin Pump Therapy TOLOCHENAZ, SWITZERLAND - June 3, 2014 - Medtronic, Inc. (NYSE:MDT) today announced the European launch of MiniMed® Duo(TM), the world's first two-in-one breakthrough that combines a glucose sensor and insulin infusion set into one on-body device, simplifying integrated insulin pump therapy and continuous glucose monitoring (CGM). MiniMed Duo, which is used with the MiniMed® Veo(TM) system, makes it easie... |
| | | | 06/03/14 | Covidien Announces CE Mark of Nellcor™ Respiration Rate Technology| System monitors respiration rate, oxygen saturation and pulse rate
from a single, finger sensor
DUBLIN, Ireland--(BUSINESS WIRE)--Jun. 3, 2014--
Covidien
plc, a leading global provider of health care products and
recognized innovator in patient monitoring and respiratory care devices,
today announced the European commercial launch of its Nellcor™
Respiration Rate System. In addition to the Adult Respiratory Sensor,
the system includes t... |
| | | | 06/02/14 | Medtronic Opens Applications for 2014 Bakken Invitation Award; Unveils Online Community to Connect People With Medical Devices Who "Live On. Give On."| (View Bakken Invitation Video (PSA) Here) Medtronic Will Donate $10 to Project HOPE for Every Story Shared Online MINNEAPOLIS - June 2, 2014- Medtronic, Inc. (NYSE: MDT) today opened 2014 award applications for the Bakken Invitation, a global program designed to celebrate and connect people who, with the help of medical technology, have overcome health challenges and are now selflessly giving back to their communities. In its second year, the Bakken Invitation Award honors ten inspirational... |
| | | | 06/02/14 | Medtronic Launches Advisa and Ensura SR MRI(TM) SureScan® Pacemaker Systems in Europe| Single-chamber Devices Receive CE Mark for Full Body MRI Scans Without Positioning Restrictions MINNEAPOLIS - June 2, 2014 - Medtronic, Inc. (NYSE: MDT), today announced CE (Conformité Européenne) Mark and commercial launch of the Advisa® and Ensura SR MRI(TM) SureScan® single chamber pacemaker devices in Europe. Both pacemakers are approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. These devices are not approved in the United States. MRI is the standard ... |
| | | | 05/22/14 | Covidien Releases Two-Year Study Results Demonstrating Sustained Effectiveness of Drug-Coated Angioplasty Balloon Technology| ILLUMENATE First-in-Human Clinical Trial Supports the Stellarex™
Balloon with EnduraCoat™ Technology in Treating Peripheral Arterial
Disease
PARIS--(BUSINESS WIRE)--May 22, 2014--
Covidien’s
Stellarex™ drug-coated angioplasty balloon (Stellarex DCB) continues to
be shown as safe and effective for treatment of peripheral arterial
disease (PAD), according to new 24-month data released today from the
company’s ILLUMENATE First-in-H... |
| | | | 05/21/14 | Medtronic CoreValve® System Demonstrates Positive Clinical Performance at Two Years in 'Real World' ADVANCE Study| Rigorous Two-Year Analyses Presented at EuroPCR 2014 Affirm Safety, Efficacy and Sustained Valve Performance of Self-Expanding Valve PARIS and MINNEAPOLIS - May 21, 2014 - Medtronic, Inc. (NYSE: MDT) today revealed new data showing that patients treated with the CoreValve® System experienced positive clinical outcomes in the rigorous "real world" Medtronic CoreValve ADVANCE Study. Presented at EuroPCR 2014, the transcatheter aortic valve implantation (TAVI) study revealed low rates o... |
| | | | 05/20/14 | Medtronic Announces CE Mark and Launch of NC Euphora(TM) Coronary Balloon| Noncompliant Balloon Provides Superior Deliverability and Controlled Growth for Challenging Coronary Angioplasty Procedures MINNEAPOLIS -- May 20, 2014 -- Continuing its commitment to bringing advanced and clinically relevant interventional technologies to market, Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européene) mark and launch of the NC Euphora(TM) Noncompliant Balloon Dilatation Catheter. The NC Euphora Balloon Catheter is now available in Europe and other countries outsi... |
| | | | 05/20/14 | Medtronic Reports Fourth Quarter and Fiscal Year 2014 Earnings| Q4 Revenue of $4.6 Billion Grew 3% at Constant Currency; 2% as Reported Q4 Non-GAAP Diluted EPS of $1.12; GAAP Diluted EPS of $0.44 FY14 Revenue of $17.0 Billion Grew 4% at Constant Currency; 3% as Reported FY14 Free Cash Flow of $4.6 Billion; GAAP Cash Flow from Operations of $5.0 Billion Company Sets Initial FY15 Revenue Growth Outlook and EPS Guidance MINNEAPOLIS - May 20, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2... |
| | | | 05/20/14 | Medtronic Settles Global Patent Litigation with Edwards Lifesciences| TAVI and Surgical Patent Cases Resolved MINNEAPOLIS - May 20, 2014 - Medtronic, Inc. (NYSE: MDT) announced that it has reached a global patent settlement agreement with Edwards Lifesciences Corporation (NYSE:EW). Under the terms of the cross-license settlement agreement, the parties will dismiss all of the pending litigation matters and patent office actions between them, and grant each other broad releases to patent litigation claims. Medtronic will pay Edwards a one-time payment of $750 mi... |
| | | | 05/19/14 | Covidien Teams with National Association of Community Health Centers on Grants to Organizations in Medically Underserved Communities| BETHESDA, MD and DUBLIN, Ireland – May 19, 2014 – Covidien, a global health care technology and medical supplies provider, and the National Association of Community Health Centers (NACHC) today announced recipients of the 2014 Covidien Challenge Grant program. These awards are the latest under a seven-year collaboration that has helped bring quality health care to underserved populations in hundreds of communities. Community Health Centers in 24 communities received challenge grants totaling mo... |
| | | | 05/19/14 | Medtronic Appoints Brad Lerman to Serve as Senior Vice President, General Counsel and Corporate Secretary| MINNEAPOLIS - May 19, 2014 - Medtronic, Inc. (NYSE: MDT) announced the appointment of Brad Lerman as senior vice president, general counsel and corporate secretary effective May 27, 2014. In this role, Lerman will report to Medtronic Chairman and CEO, Omar Ishrak. As senior vice president, general counsel and corporate secretary, Lerman will lead the global legal function across the company. In addition, he will direct Medtronic's government affairs department and serve as a member of Medtronic... |
| | | | 05/19/14 | Medtronic Applauds AACE/ACE on Their Updated Insulin Pump Therapy Consensus Statement| MINNEAPOLIS - May 19, 2014 - Medtronic, Inc. (NYSE:MDT) applauds the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) on their updated consensus statement on insulin pump therapy. In addition to continued support of insulin pump therapy for people with type 1 diabetes, AACE and ACE recognize the clinical value of insulin pumps in improving glucose control for those with intensively managed insulin-dependent type 2 diabetes. Improving glucos... |
| | | | 05/14/14 | Arizona Manufacturers Council Names Medtronic's Tempe Campus 2014 Manufacturer of the Year| TEMPE, ARIZ. - May 14, 2014 - The Medtronic Tempe Campus, a manufacturing site for the world's leading medical technology company, has been named 2014 Manufacturer of the Year by the Arizona Manufacturers Council. The campus, located on a 30-acre site southeast of Phoenix Sky Harbor International Airport, is home to a world-class microelectronics manufacturing facility and technology center. "For this prestigious award, we select a manufacturer that produces superior products, provides hi... |
| | | | 05/13/14 | Medtronic to Announce Financial Results for Its Fourth Quarter and Fiscal Year 2014| MINNEAPOLIS - May 13, 2014 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the fourth quarter and fiscal year 2014 on Tuesday, May 20, 2014. A news release will be issued at approximately 6:15 a.m. Central Daylight Time and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic's fourth quarter and fiscal year, which ended April 25, 2014. Medtronic will host a webcast at 7 a.m. Cen... |
| | | | 05/13/14 | Medtronic Names Hooman Hakami Executive Vice President and Group President of the Medtronic Diabetes Group| MINNEAPOLIS - May 13, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the selection of Hooman Hakami as executive vice president and group president of the Medtronic Diabetes Group, the global leader in insulin pumps and continuous glucose monitoring systems. In this role, Hakami will lead Medtronic's entire global diabetes franchise, including research and development, operations, and sales and marketing. Hakami previously served as president and CEO of GE Healthcare's Detection and Guidan... |
| | | | 05/10/14 | Late-Breaking Clinical Trial Results Show Medtronic-Exclusive Pacemaker Algorithm Significantly Delays Atrial Fibrillation| MINERVA Trial Presented at Heart Rhythm Meeting Shows Medtronic Advanced Pacing Features Reduce the Progression of Persistent AF by 58 Percent While Reducing AF-Related Hospital Visits That Lead to Increased Healthcare Costs MINNEAPOLIS and SAN FRANCISCO - May 10, 2014 - New data presented as a late-breaking clinical trial at the Heart Rhythm Society's 2014 Annual Scientific Sessions show that an advanced pacing feature exclusive to Medtronic, Inc. (NYSE: MDT) pacemakers significantly delays t... |
| | | | 05/10/14 | New Data Show That Defibrillators Programmed to Wait Longer to Deliver Therapy Are Safe for Secondary Prevention ICD Patients with Medtronic SmartShock Technology| Late-breaking Clinical Trial Data Confirm Industry Leadership with 1 Percent Inappropriate Shocks Using Medtronic SmartShock Technology MINNEAPOLIS and SAN FRANCISCO - May 10, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the results from the first prospective randomized clinical trial to show that Medtronic implantable cardioverter defibrillators (ICDs) can safely extend detection times before triggering therapy in secondary prevention patients. The results of the PainFree SST sub-study, ... |
| | | | 05/09/14 | Medtronic Announces 2014 Analyst Meeting and Webcast| MINNEAPOLIS - May 9, 2014 - Medtronic (NYSE: MDT) will host an institutional investor and analyst meeting on Thursday, June 5, 2014, in New York City from 8:30 a.m. to approximately 1:00 p.m. Eastern Daylight Time. The meeting will include remarks from the Medtronic management team highlighting the company's strategy for executing on its growth vectors to expand its market leadership position, delivering consistent and reliable performance, and creating long-term shareholder value. Medtronic... |
| | | | 05/09/14 | Study Shows Promising Results with Novel Approach to Medtronic Cardiac Resynchronization Therapy| Late-Breaking Clinical Trial Data Show Implant Success with Pacing Inside the Left Ventricle in Heart Failure Patients MINNEAPOLIS and SAN FRANCISCO - May 9, 2014 - Medtronic, Inc. (NYSE: MDT) today released study findings that show heart failure patients who have limited options for implanted device therapy may benefit from a novel implant technique for cardiac resynchronization therapy (CRT) devices. Data from the ALSYNC (Alternate Site Cardiac Resynchronization) study show that pacing from ... |
| | | | 05/09/14 | HeartWare Presentation At The Bank Of America Merrill Lynch 2014 Health Care Conference To Be Webcast| FRAMINGHAM, Mass., May 9, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference at 12:00 p.m. PDT (3:00 p.m. EDT) on Tuesday, May 13, 2014. The conference is being held May 12-15 at the Encore at Wynn in Las V... |
| | | | 05/07/14 | Covidien Opens Advanced Medical Training and Research Center in Turkey| ISTANBUL--(BUSINESS WIRE)--May 7, 2014--
Further expanding its training and research capabilities in emerging
markets, Covidien
plc (NYSE: COV), has officially opened its Covidien Center of Innovation
Turkey (CCI Turkey). Located in Istanbul, the new facility offers
clinicians in Turkey and the surrounding region training on advanced
procedures and techniques using the latest technology.
“At Covidien we constantly challenge each other to r... |
| | | | 05/06/14 | Medtronic Agrees to Settle Certain INFUSE® Bone Graft Product Liability Cases| MINNEAPOLIS - MAY 6, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has agreed with certain plaintiffs' counsel to settle their inventories of filed and unfiled product liability claims related to INFUSE® Bone Graft. Under the terms of the agreement, Medtronic has agreed, subject to certain conditions, to resolve the claims of an estimated 950 claimants for a total payment of approximately $22 million. This agreement is a compromise of disputed claims and is not in any way an adm... |
| | | | 05/06/14 | Covidien to Present at Bank of America Merrill Lynch 2014 Health Care Conference| DUBLIN, Ireland--(BUSINESS WIRE)--May 6, 2014--
Covidien
plc (NYSE: COV) will present at the Bank of America Merrill Lynch 2014
Health Care Conference in Las Vegas on May 14. Bryan Hanson, group
president, Medical Devices and U.S. will discuss the company in a
presentation scheduled to begin at 1:40 p.m. PT (4:40 p.m. ET).
A live audio webcast of the presentation can be accessed at Covidien’s
Investor Relations website: http://investor.cov... |
| | | | 05/01/14 | Ten Local High School Graduates Named 2014 Medtronic Wallin Scholars| Medtronic has committed more than $1.7 million in local scholarships to 110 students. MINNEAPOLIS - May 1, 2014 - Medtronic today announced that 10 students have been selected as 2014 Medtronic Wallin Scholars. Each will receive a four-year scholarship totaling $16,000, as well as support services to assist them in their collegiate studies. Students represent nine Twin Cities' north suburban high schools, and one Minneapolis high school. The class of 2014 Medtronic Wallin Scholars will be honor... |
| | | | 05/01/14 | Medtronic Viva® Cardiac Resynchronization Therapy-Pacemaker Now Available in Europe| New Device Automatically Adapts to Patient Needs, Continuously Optimizes Therapy,Improves Response Rate and Reduces Heart Failure Hospitalizations MINNEAPOLIS, MAY 1, 2014 - Medtronic, Inc. (NYSE:MDT) today announced CE (Conformité Européenne) Mark receipt and the European launch of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P. The Viva CRT-P is not approved for sale in the United States. The Viva CRT-P includes the Medtronic-exclusive AdaptivCRT® software, which is the... |
| | | | 05/01/14 | Covidien to Present at Deutsche Bank Health Care Conference| DUBLIN, Ireland--(BUSINESS WIRE)--May 1, 2014--
Covidien
plc (NYSE: COV) will present at the Deutsche Bank 39th Annual Health
Care Conference in Boston on May 8. Charles J. Dockendorff, executive
vice president and chief financial officer, will discuss the company in
a presentation scheduled to begin at 2:10 p.m. ET.
A live audio webcast of the presentation can be accessed at Covidien’s
Investor Relations website: http://investor.covidien.... |
| | | | 05/01/14 | HeartWare International Reports $66.5 Million In First Quarter 2014 Revenue; 35% Increase From First Quarter 2013| - Record 665 HeartWare® Ventricular Assist Systems sold worldwide in Q1; exceeds previous quarterly high of 549 units
- U.S. revenue of $33.8 million, 29% growth from first quarter 2013
- International revenue of $32.7 million, 42% growth from first quarter 2013
- Conference call today at 8:00 a.m. U.S. EDT -
FRAMINGHAM, Mass., May 1, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologie... |
| | | | 05/01/14 | HeartWare International Issues Voluntary Device Correction For HeartWare® Batteries| FRAMINGHAM, Mass., May 1, 2014 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR), today issued a voluntary Urgent Medical Device Correction related to all HeartWare® Ventricular Assist System batteries, product codes 1650 and 1650-DE. In letters to clinicians and patients, the company reports an observed increase in complaints related to earlier-than-expected battery depletion and routine battery handling.
HeartWare is providing information to assist patients and clinicians in mon... |
| | | | 04/29/14 | Medtronic Reveals Positive Outcomes for CoreValve® Patients Treated via Alternative Access Routes| AATS Late-Breaker Data Show Strong Clinical Results in Complex Patient Population TORONTO and MINNEAPOLIS - April 29, 2014 - Medtronic, Inc. (NYSE: MDT) today revealed new data demonstrating positive outcomes for extreme risk patients with severe aortic stenosis who were treated with the CoreValve® System via alternative access approaches. The compelling data were unveiled during a late-breakin... |
| | | | 04/29/14 | Medtronic Sutureless Heart Valve First to Show Five-Year Safety and Efficacy Outcomes| Less-Invasive Surgical Aortic Valve Demonstrates Sustained Durability MINNEAPOLIS - April 29, 2014 -Medtronic, Inc. (NYSE: MDT) today announced five-year follow-up data demonstrating the safety and performance of the Medtronic 3f Enable® Aortic Bioprosthesis - the world's first commercially available sutureless tissue heart valve. The longest follow-up data ever reported for a sutureless bioprosthesis, results showed that patients implanted with 3f Enable displayed no structural valve deterio... |
| | | | 04/28/14 | Medtronic Among Top U.S. Corporate Citizens, According to Corporate Responsibility Magazine| MINNEAPOLIS - April 28, 2014 - Medtronic has been recognized as a top U.S. corporate citizen by Corporate Responsibility Magazine. The publication's 100 Best Corporate Citizens List, released this week, recognizes companies for their commitment to the environment, climate change, employee relations, human rights, governance, finance and philanthropy. Corporate Responsibility magazine's rating is based on publicly available information and is recognized as one of the nation's top measurements o... |
| | | | 04/25/14 | Covidien Reports Second-Quarter Fiscal 2014 Results| Net sales up 3% (up 4%, excluding foreign exchange rate movement)
Second-quarter diluted GAAP earnings per share were $0.97;
excluding specified items, adjusted diluted earnings per share were
$0.96
DUBLIN, Ireland--(BUSINESS WIRE)--Apr. 25, 2014--
Covidien
plc (NYSE: COV) today announced financial results for the second quarter
of fiscal 2014. Second-quarter net sales of $2.60 billion increased 3%
from the... |
| | | | 04/24/14 | HeartWare Issues Reminder To December 2013 Driveline Connector Device Correction| FRAMINGHAM, Mass., April 24, 2014 /PRNewswire/ -- HeartWare International, Inc. (Nasdaq: HTWR) today announced issuance of a clinician and patient reminder concerning the Urgent Medical Device Correction distributed to all of its clinical sites by the company in December 2013. The device correction discussed eight complaints that the locking mechanism of the driveline connector of the HeartWare® Ventricular Assist System had failed to engage and instructed clinicians to inspect patient drivelin... |
| | | | 04/22/14 | HeartWare Schedules First Quarter Conference Call And Webcast| FRAMINGHAM, Mass., April 22, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2014, at 8:00 a.m. U.S. Eastern Daylight Time on Thursday, May 1, 2014. The Company plans to release the financial results prior to the conference call.
The conference call with management will discuss the Company's financial results, highlights from the first quarter and business outlook. The call... |
| | | | 04/22/14 | Medtronic Announces First U.S. Implant of Implantable Cardioverter-Defibrillator System Designed to Allow Full-Body MRI Scans| First Patient Enrolled in U.S. Pivotal Clinical Trial to Evaluate the Evera MRI(TM) ICD System MINNEAPOLIS - April 22, 2014 -Medtronic today announced the first U.S. implant of the Evera MRI(TM) SureScan® implantable cardioverter-defibrillator (ICD) System, following U.S. Food and Drug Administration (FDA) approval for its Investigational Device Exemption (IDE) application and pivotal clinical trial protocol. Evera MRI is the first ICD system to be evaluated in the U.S. that allows for magnetic... |
| | | | 04/21/14 | Federal Appeals Court Agrees to Medtronic Request to Postpone Injunction| MINNEAPOLIS - April 21, 2014 - The Federal Circuit Court of Appeals today granted a request from Medtronic, Inc. (NYSE: MDT) to postpone the implementation of an injunction that would have prevented the company from selling its CoreValve® System in the United States. This means the injunction will only take effect if the appellate court determines the injunction was properly issued. In addition, last week the Court of Appeals agreed to an expedited appeal of the injunction ruling, with the las... |
| | | | 04/21/14 | Update on CoreValve Federal District Court Ruling; Court Agrees to Expedited Appeal | MINNEAPOLIS - April 21, 2014 - Medtronic, Inc. (NYSE: MDT) today issued an updated statement on the recent ruling by Federal District Court of Delaware. The ruling granted in part Edwards Lifesciences' motion for a preliminary injunction that prevents Medtronic from selling or offering to sell its CoreValve® System in the United States, except through a mechanism that Medtronic is pursuing with Edwards Lifesciences that would allow currently trained sites to treat patients with CoreValve based o... |
| | | | 04/18/14 | Endurant AAA Stent Graft from Medtronic Continues Exceptional Long-Term Performance in Observational Studies| New Clinical Data from PANDORA and ENGAGE Affirm Market-Leading Medical Device's Durable, Consistent and Proven Outcomes In Endovascular Treatment of Abdominal Aortic Aneurysms MINNEAPOLIS -- April 18, 2014 -- The Endurant AAA stent graft system from Medtronic, Inc. (NYSE: MDT) continues to demonstrate exceptional long-term performance in the endovascular treatment of abdominal aortic aneurysms, according to new clinical data presented for the first time at the 2014 Charing Cross international... |
| | | | 04/14/14 | Covidien Announces U.S. Food and Drug Administration 510(k) Clearance for the Kangaroo™ Feeding Tube with IRIS Technology| New feeding tube with integrated camera designed to deliver
enhanced patient safety
DUBLIN, Ireland--(BUSINESS WIRE)--Apr. 14, 2014--
Covidien
plc (NYSE: COV) today announced U.S. Food and Drug Administration 510(k)
Clearance for the Kangaroo™ feeding tube with IRIS Technology. This
first-of-its-kind camera-equipped disposable feeding tube is designed to
enhance patient safety by providing visualization for a procedure that
is currently... |
| | | | 04/11/14 | Medtronic to Appeal Federal District Court Ruling| MINNEAPOLIS - April 11, 2014 - The Federal District Court of Delaware today granted in part Edwards Lifesciences' motion for a preliminary injunction that prevents Medtronic, Inc. (NYSE: MDT) from selling or offering to sell its CoreValve® System in the United States. Today's ruling has no impact on the sale or marketing of CoreValve outside of the United States or the use of CoreValve in the current U.S. clinical trials. At Medtronic's request, the Federal District Court agreed to postpone the... |
| | | | 04/11/14 | Covidien Implements Voluntary Recall of its Pipeline™ Embolization Device and Alligator™ Retrieval Device| DUBLIN, Ireland--(BUSINESS WIRE)--Apr. 11, 2014--
Covidien plc today announced that it has notified customers of a
voluntary recall to address an issue with certain lots of its Pipeline™
Embolization Device and Alligator™ Retrieval Device where the
polytetrafluoroethylene (PTFE) coating applied to the delivery wire
could delaminate and detach from the devices.
PTFE coating is used to reduce friction between devices and ease
navigation thro... |
| | | | 04/10/14 | Medtronic CRT Devices Now Approved to Treat Patients with AV Block and Reduced Heart Function| Landmark BLOCK HF Trial Demonstrates Clinical Benefits of Biventricular Pacing in New Patient Population MINNEAPOLIS - April 10, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization therapy-pacemakers and -defibrillators (CRT-P and CRT-D). Medtronic CRT devices are now approved to treat patients with atrioventricular (AV) block and left ventricul... |
| | | | 04/09/14 | Medtronic Announces CE Mark and European Launch of First Implantable Cardioverter-Defibrillator System to Allow for Full-Body MRI Scans| Evera MRI(TM) ICD System Is First to Combine Proven Treatment Performance, Increased Longevity, Improved Comfort with Full-Body MRI Access MINNEAPOLIS - April 9, 2014 - Medtronic today announced CE (Conformité Européenne) Mark and European launch of the Evera MRI(TM) SureScan® implantable cardioverter-defibrillator (ICD) System, the first and only ICD system approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. The Medtronic Evera MRI ICD is not approved in t... |
| | | | 04/07/14 | Medtronic Acquires Majority of the Shares of Biostar Creating a New Medtronic-Medicall Collaboration in Turkey| ISTANBUL - April 7, 2014 - Medtronic, Inc. today announced that one of its subsidiaries has acquired a majority of the shares of Biostar, which will assume the distribution of Medtronic products in Turkey formerly distributed by Medicall Biomedikal A.S., creating a new collaboration between Medtronic and Medicall in Turkey. The transaction is intended to support Medtronic's strategy to get even closer to the customer, improve and increase efforts in market development, and accelerate growth. T... |
| | | | 04/05/14 | 'IN.PACT Admiral' Drug-Coated Balloon From Medtronic Outperforms Standard Angioplasty In Landmark Study| Interventional Treatment of Lower-Extremity Peripheral Arterial DiseaseWith Novel Medical Device Shows Positive Results in IN.PACT SFA Trial LONDON -- April 5, 2014 --Patients with peripheral artery disease in the upper leg experienced significantly better outcomes at 12 months after treatment with the IN.PACT Admiral drug-coated balloon from Medtronic, Inc. (NYSE: MDT) than with standard balloon angioplasty, according to a landmark clinical study reported on today for the first time. The IN.P... |
| | | | 03/31/14 | Medtronic CoreValve® System Demonstrates Long-Term Durability| Final Follow-up of CoreValve CE Pivotal Study Shows Sustained Valve Function MINNEAPOLIS - March 31, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the final follow-up results from the CoreValve® CE Pivotal Study, which demonstrated excellent long-term durability at four years in patients with severe aortic stenosis who were treated with the self-expanding CoreValve System. The results were presented for the first time at the 63rd Annual Scientific Session of the American College of Cardi... |
| | | | 03/30/14 | Medtronic Global SYMPLICITY Registry Shows Strong Safety Profile of the Symplicity(TM) Renal Denervation System| Six-Month Analysis of First 1,000 Patients Enrolled in Real-World Patient Registry Presented at ACC.14 MINNEAPOLIS and WASHINGTON, D.C. - March 30, 2014 - Medtronic, Inc. (NYSE: MDT), announced today further analysis of six-month follow-up data from the first 1,000 patients enrolled in the Global SYMPLICITY Registry, which continue to demonstrate the safety of the Symplicity(TM) renal denervation system. Presented today during a late-breaking clinical trial session at the 63rd Scientific Sessio... |
| | | | 03/30/14 | World's First Transcatheter Valve, Medtronic Melody® Transcatheter Pulmonary Valve Shows Positive Clinical Outcomes in Real-World Study| Has Repaired Hearts of 6,000+ Patients; More Than Half Are Children MINNEAPOLIS and WASHINGTON - March 30, 2014 - Medtronic, Inc. (NYSE: MDT), today announced the one-year results of the Melody® Transcatheter Pulmonary Valve (TPV) U.S. Post-Approval Study, which found that real-world use of the Melody TPV was associated with high procedural success, excellent valve function and few repeat procedures at the primary endpoint of six months. These results were sustained out to one year. The Melod... |
| | | | 03/29/14 | Medtronic CoreValve® System Results Superior to Open-Heart Surgery at One Year in U.S. Pivotal Trial| CoreValve High Risk Study: FDA Determines Expert Panel Not Required Low Mortality Rate Exceeds Expectations for Primary Endpoint CoreValve System is First and Only Transcatheter Aortic Valve to Show Results Superior to Surgical Aortic Valve Replacement MINNEAPOLIS and WASHINGTON - March 29, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the CoreValve® System showed results superior to surgical aortic valve replacement (SAVR) at one year in the High Risk Study of its CoreValve U.... |
| | | | 03/29/14 | Medtronic Releases Results of SYMPLICITY HTN-3| Medtronic Commits to Further Clinical Investigation and Determining Path Forward for Next U.S. IDE with FDA MINNEAPOLIS and WASHINGTON, DC - March 29, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the full results of the SYMPLICITY HTN-3 clinical trial, which were presented today in late-breaking session at the 63rd Scientific Sessions of the American College of Cardiology (ACC) and published simultaneously in The New England Journal of Medicine. SYMPLICITY HTN-3, the first and only blind... |
| | | | 03/28/14 | AORN Foundation, Covidien Team to Offer New Tools for Emerging Nurse Leaders| DENVER, Colo. and DUBLIN, Ireland – March 28, 2014 – In a move aimed at giving nursing professionals the tools they need to address rapidly changing practices and cost structures, the AORN Foundation is teaming with Covidien on an initiative that will provide nurse leaders with a core set of financial and management tools to complement their clinical expertise. The new AORN Emerging Leaders educational initiative will comprise five day-long seminars focusing on leadership development and financi... |
| | | | 03/27/14 | First Patients Enrolled in Medtronic Clinical Study Designed to Identify Patients at High Risk for Sudden Cardiac Arrest in Developing Countries| Study Will Assess Defibrillator Therapy in Patients Most At-Risk for SCA Minneapolis - March 27, 2014 -Medtronic, Inc. (NYSE:MDT) today announced the first patients were enrolled in the Improve SCA Clinical Study, a first-of-its-kind study that will identify patients in developing countries at a high risk for sudden cardiac arrest (SCA) - an abrupt loss of heart function that can lead to death in minutes - who have not previously experienced a life threatening arrhythmia (primary prevention p... |
| | | | 03/25/14 | Study Published in JAMA Shows Covidien Endoscopic Ablation Therapy Effective In Treating Barrett’s Esophagus| DUBLIN--(BUSINESS WIRE)--Mar. 25, 2014--
An innovative Covidien
(NYSE: COV) technology is effective at treating Barrett’s esophagus (a
precancerous condition of the esophagus), according to a clinical study
published in The Journal of the American Medical Association
(JAMA).
The March 25 JAMA publication announced results from the SURF Trial (SUrveillance
vs. RadioFrequency
ablation). SURF was a multi-center, randomized, investigato... |
| | | | 03/19/14 | Covidien Announces Results from 2014 Annual General Meeting| DUBLIN, Ireland--(BUSINESS WIRE)--Mar. 19, 2014--
Covidien
plc (NYSE: COV) announced the results from today’s Annual General
Meeting. Seven proposals were on the meeting agenda:
Election of Directors
Appointment of Independent Auditors
An advisory vote to approve the company’s executive compensation
Authorization of the company and/or any subsidiary to make market
pur... |
| | | | 03/19/14 | Covidien Declares Quarterly Cash Dividend| DUBLIN, Ireland--(BUSINESS WIRE)--Mar. 19, 2014--
Covidien
plc (NYSE:COV) today announced that its Board of Directors has declared
a quarterly cash dividend of $0.32 per ordinary share. The dividend is
payable on May 5, 2014, to shareholders of record on April 7, 2014.
About Covidien
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
val... |
| | | | 03/14/14 | Covidien plc to Report Second-Quarter Fiscal 2014 Results on April 25, 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Mar. 14, 2014--
Covidien
plc (NYSE: COV) will report second-quarter fiscal 2014 results on April
25. The company will host a conference call for investors at 8:30 a.m.
ET. The call can be accessed in the following ways:
Via webcast at Covidien’s website: http://investor.covidien.com
By telephone: For both “listen-only” participants and those
participants who wish to take part ... |
| | | | 03/13/14 | Covidien Launches Symbotex™ Composite Mesh for Surgical Laparoscopic and Open Ventral Hernia Repair| Innovative Mesh Designed to Simplify Surgeon Experience, Offer
Patients Optimal Hernia Repairs
DUBLIN, Ireland--(BUSINESS WIRE)--Mar. 13, 2014--
Further strengthening its broad line of hernia repair products, Covidien
plc (NYSE: COV) today announced the U.S. launch of Symbotex™
composite mesh, an innovative product designed to make it easier for
surgeons to perform surgical laparoscopic and open ventral hernia
repairs.
Symbote... |
| | | | 03/10/14 | Medtronic Seeking Long-Distance Runners Who Benefit From Medical Technology| "Global Heroes" Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in October MINNEAPOLIS - March 10, 2014 - Medtronic, Inc. (NYSE: MDT) announced today applications are open to runners around the world who benefit from medical technology to represent their country on the 2014 Medtronic Global Heroes team. Up to 25 runners will be selected to receive a paid entry for themselves and a guest to the Medtronic Twin Cities Marathon or the Medtronic TC 10 Mile an... |
| | | | 03/07/14 | HeartWare Presentation At The 2014 Barclays Global Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., March 7, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2014 Barclays Global Healthcare Conference at 10:15 a.m. EDT on Tuesday, March 11, 2014. The conference is being held March 11-13 at Loews Miami Hotel.
A live webcast of the Company'... |
| | | | 03/06/14 | Medtronic CFO Gary Ellis to Speak at Barclays Global Healthcare Conference| MINNEAPOLIS - Mar 6, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Barclays Global Healthcare Conference on Wednesday, March 12, 2014, in Miami. Gary Ellis, senior vice president and chief financial officer of Medtronic, will make a presentation about Medtronic beginning at 4:15 p.m. EDT (3:15 p.m. CDT). A live audio webcast of the presentation will be available on March 12, 2014, by clicking on the Investors lin... |
| | | | 03/06/14 | Medtronic Wins European Patent Office Ruling| MINNEAPOLIS - March 6, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that the European Patent Office (EPO) has invalidated, in its entirety, the Edwards Lifesciences EP2055266 Spenser patent which was the basis for the Aug. 26, 2013 injunction prohibiting sales of the CoreValve® System in Germany. In its ruling, the EPO in The Hague said the entire patent is invalid and therefore revoked. "Medtronic is very pleased with this ruling as it will ensure that patients across Europe who n... |
| | | | 03/06/14 | Covidien to Present at Barclays Global Healthcare Conference 2014| DUBLIN, Ireland--(BUSINESS WIRE)--Mar. 6, 2014--
Covidien
plc (NYSE: COV) will present at the Barclays Global Healthcare
Conference 2014 in Miami on March 13. Charles J. Dockendorff, executive
vice president and chief financial officer, will discuss the company in
a presentation scheduled to begin at 10:45 a.m. ET.
A live audio webcast of the presentation can be accessed at Covidien’s
Investor Relations website: http://investor.covidien.co... |
| | | | 03/03/14 | Aetna and Medtronic Collaborate to Help Members Take Better Control of Type 2 Diabetes| - Program Aims to Improve Patients' Quality of Life and Enhance Support for Doctors to Help Create More Value in the Health Care System - HARTFORD, Conn. and MINNEAPOLIS, March 3, 2014 - Beginning this month, Aetna (NYSE: AET) and Medtronic, Inc. (NYSE: MDT) will work with doctors in a new program to reach up to 300 fully insured members with uncontrolled type 2 diabetes who may improve their health using insulin pump therapy. Eligible members will receive targeted education, case management a... |
| | | | 03/03/14 | Covidien Announces CE Mark Approval for Puritan Bennett™ 980 Ventilator| New acute care ventilator delivers advanced breath technology for
enhanced patient comfort and clinician ease of use
DUBLIN, Ireland--(BUSINESS WIRE)--Mar. 3, 2014--
Covidien
plc (NYSE: COV), a leading global provider of healthcare products and
recognized innovator in patient monitoring and respiratory care devices,
today announced its Puritan Bennett™ 980 ventilator has received
European Economic Area (EEA) CE Mark approval.
Pu... |
| | | | 02/27/14 | Medtronic EVP & President Mike Coyle to Speak at Cowen Healthcare Conference| MINNEAPOLIS - Feb 27, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the Cowen and Company 34th Annual Healthcare Conference on Wednesday, March 5, 2014, in Boston. Mike Coyle, executive vice president and president of Medtronic's Cardiac and Vascular Group, will make a presentation about Medtronic beginning at 11:20 a.m. EST (10:20 a.m. CST). A live audio webcast of the presentation will be available on March 5, 2014... |
| | | | 02/27/14 | HeartWare International Reports Fourth Quarter 2013 Results| - U.S. revenue increased 94% in fourth quarter 2013 to $25.9 million, from $13.4 million in fourth quarter of 2012
- Revenue for 2013 increased 87% to $208 million from $111 million in 2012, reflects first year of commercialization in U.S.
- Conference call today at 8:00 a.m. U.S. EST -
FRAMINGHAM, Mass., Feb. 27, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizi... |
| | | | 02/27/14 | Covidien Completes Acquisition of Given Imaging| DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 27, 2014--
Covidien plc (NYSE: COV) today announced that it has closed its
acquisition of Given Imaging Ltd., providing the company additional
scale and scope to serve a significant medical specialty, the
multibillion dollar global gastrointestinal (GI) market.
PillCam SB is the most widely used, patient-friendly tool for directly visualizing the small bowel to detect and monitor abnormalities. This procedure is th... |
| | | | 02/26/14 | Covidien Announces U.S. Food and Drug Administration 510(k) Clearance for the Puritan Bennett™ 980 Ventilator| New acute care ventilator delivers advanced breath technology for
enhanced patient comfort and clinician ease of use
DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 26, 2014--
Covidien
plc (NYSE: COV), a leading global provider of healthcare products and
recognized innovator in patient monitoring and respiratory care devices,
today announced its Puritan Bennett™ 980 ventilator has received U.S.
Food and Drug Administration (FDA) 510(k) clearance.
... |
| | | | 02/26/14 | HeartWare Presentation At The Raymond James 35th Annual Institutional Investors Conference To Be Webcast| FRAMINGHAM, Mass., Feb. 26, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Raymond James 35th Annual Institutional Investors Conference at 4:35 p.m. EST on Tuesday, March 4, 2014. The conference is being held March 2-5 at JW Marriott Grande Lakes, Orlando, Fl... |
| | | | 02/24/14 | Covidien to Present at Raymond James 35th Annual Institutional Investors Conference| DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 24, 2014--
Covidien
plc (NYSE: COV) will present at the Raymond James 35th Annual
Institutional Investors Conference in Orlando, Fla., on March 3. Charles
J. Dockendorff, executive vice president and chief financial officer,
will discuss the company in a presentation scheduled to begin at 9:50
a.m. ET.
A live audio webcast of the presentation can be accessed at Covidien’s
Investor Relations web... |
| | | | 02/21/14 | Medtronic Announces Public Offering of Senior Notes| MINNEAPOLIS -- February 21, 2014 -- On February 20, 2014, Medtronic, Inc. (NYSE: MDT) registered an offering of $250 million principal amount of its 0.875% Senior Notes due 2017, $250 million principal amount of its floating rate Senior Notes due 2017, $850 million principal amount of its 3.625% Senior Notes due 2024, and $650 million principal amount of its 4.625% Senior Notes due 2044 (collectively, the "Notes"). The closing of the offering is expected to occur on February 27, 2014,... |
| | | | 02/20/14 | Medtronic Announces First U.S. Implant of World's Smallest, Minimally Invasive Cardiac Pacemaker| Medtronic Enrolls First U.S. Patient in Global Clinical Trial for Miniature Transcatheter Pacemaker System MINNEAPOLIS - Feb. 20, 2014 - Continuing its leadership in advanced pacing technology and device miniaturization, Medtronic, Inc. (NYSE: MDT), today announced the first U.S. implant of the world's smallest pacemaker: the Micra(TM) Transcatheter Pacing System (TPS). The device was successfully implanted at NYU Langone Medical Center by Larry Chinitz, M.D., director of the Heart Rhythm Cente... |
| | | | 02/19/14 | Medtronic Announces Global Launch of Miniature Cardiac Monitor, Reveal LINQ(TM) ICM| Small, Wireless Monitor Provides Long-Term Remote Monitoring to Help Physicians Diagnose and Monitor Irregular Heartbeats MINNEAPOLIS - February 19, 2014 -Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance, CE (Conformité Européenne) Mark, and the global launch of its Reveal LINQ Insertable Cardiac Monitor (ICM) System, the smallest implantable cardiac monitoring device available for patients. The Reveal LINQ ICM is approximately one-third t... |
| | | | 02/18/14 | Medtronic EVP & President Chris O'Connell to Speak at Citi Global Healthcare Conference| MINNEAPOLIS - Feb 18, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 2014 Citi Global Healthcare Conference on Monday, February 24, 2014, in New York City. Chris O'Connell, executive vice president and president of Medtronic's Restorative Therapy Group, will make a presentation about Medtronic beginning at 3:30 p.m. EST (2:30 p.m. CST). A live audio webcast of the presentation will be available on February 24, 201... |
| | | | 02/18/14 | Covidien to Present at Upcoming Investor Conferences| DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 18, 2014--
Covidien
plc (NYSE: COV) will present at two upcoming investor conferences -- the
Citi 2014 Global Healthcare Conference on Feb. 25 and the RBC Capital
Markets 2014 Global Healthcare Conference on Feb. 26.
Citi 2014 Global Healthcare Conference
Joe Almeida, chairman,
president and chief executive officer
Feb. 25, 8:00 a.m. ET
New
York
RBC Ca... |
| | | | 02/18/14 | Medtronic Reports Third Quarter Earnings| Revenue of $4.2 Billion Grew 4% on a Constant Currency Basis; 3% as Reported Non-GAAP Diluted EPS of $0.91; GAAP Diluted EPS of $0.75 Free Cash Flow of $1.5 Billion; GAAP Cash Flow from Operations of $1.6 Billion Reiterates FY14 Revenue Outlook; Tightens FY14 Diluted EPS Guidance MINNEAPOLIS - Feb. 18, 2014 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2014, which ended January 24, 2014. The company reported worldwide third quarter ... |
| | | | 02/14/14 | Study Finds Medtronic Insertable Cardiac Monitors Detect Atrial Fibrillation In Stroke Patients Better Than Standard Care| MINNEAPOLIS - February 14, 2014 - Medtronic, Inc. (NYSE: MDT), today announced results from the CRYSTAL AF (CRYptogenic STroke And underLying Atrial Fibrillation) Clinical Trial, which found that continuous cardiac monitoring with the Reveal® XT Insertable Cardiac Monitor (ICM) was superior to standard care at detecting atrial fibrillation (AF) in patients who have had strokes of undetermined causes (cryptogenic stroke). Presented at a late-breaking science session at the American Stroke As... |
| | | | 02/13/14 | Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2014| MINNEAPOLIS - February 13, 2014 - The board of directors of Medtronic, Inc. (NYSE:MDT) today approved a cash dividend of $0.28 per share of the Company's common stock. The quarterly dividend represents an 8% increase over the prior year. The dividend is payable on April 25, 2014, to shareholders of record at the close of business on April 4, 2014. Medtronic, a constituent of the S&P 500 Dividend Aristocrat index, remains committed to returning 50% percent of its free cash flow to shareholders th... |
| | | | 02/13/14 | Medtronic Begins Distribution of i-port Advance® Injection Port Device for People with Diabetes | Distribution Rights Broaden Medtronic's Diabetes Management Solutions to Include Injection Therapy Assistance MINNEAPOLIS - February 13, 2014 - Medtronic, Inc. (NYSE:MDT) has begun distribution of i-port Advance® as part of a continued focus to provide meaningful therapy management solutions for people with diabetes. i-port Advance can be used for people on insulin injection therapy who want to administer insulin conveniently while eliminating the need to puncture the skin with each dose of med... |
| | | | 02/13/14 | Medtronic Launches 'TOTAL Across' Crossing Catheter in Europe| New Peripheral Device Targets Challenging Lesions in Lower-Extremity, Including Below-the-Knee, Arteries Associated with Critical Limb Ischemia MINNEAPOLIS -- Feb. 13, 2014 -- Aligned with its commitment to provide innovative medical technology for the interventional treatment of peripheral artery disease, Medtronic, Inc. (NYSE: MDT) has initiated the European launch of the TOTAL across crossing catheter, which recently received the CE (Conformité Européene) mark as a tool for improving bl... |
| | | | 02/11/14 | Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2014| MINNEAPOLIS - Feb. 11, 2014 - Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2014 on Tuesday, February 18, 2014. A news release will be issued at approximately 6:15 a.m. CST and will be available at http://newsroom.medtronic.com. The earnings news release will include summary financial information for Medtronic's third quarter, which ended January 24, 2014. Medtronic will host a webcast at 7:00 a.m. CST to discuss financial ... |
| | | | 02/06/14 | Covidien Receives U.S. FDA 510(k) Clearance for Reinforced Stapling Reload Technology| Endo GIA™ Reinforced Reload with Tri-Staple™ technology integrates
tissue reinforcement buttressing capability with surgical stapling device
DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 6, 2014--
Covidien
plc. (NYSE:COV) announced that the U.S. Food and Drug Administration has
granted 510(k) clearance for the company’s Endo GIA™ Reinforced Reload
with Tri-Staple™ technology. This clearance extends Covidien’s
industry-leading portfolio of advanced su... |
| | | | 02/04/14 | HeartWare Schedules Fourth Quarter Conference Call And Webcast| FRAMINGHAM, Mass., Feb. 4, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended December 31, 2013, at 8:00 a.m. U.S. Eastern Standard Time on Thursday, February 27, 2014. The Company plans to release the financial results prior to the conference call.
The conference call with management will discuss the Company's financial results, highlights from the fourth quarter and business outlook. ... |
| | | | 02/04/14 | HeartWare Presentation At The 2014 Leerink Global Healthcare Conference To Be Webcast| FRAMINGHAM, Mass., Feb. 4, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ:HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the 2014 Leerink Global Healthcare Conference at 8:55 a.m. EST on Thursday, February 13, 2014. The conference is being held February 12-13 at the Waldorf Astoria in New York City.
A live ... |
| | | | 02/04/14 | Covidien to Present at 2014 Leerink Global Healthcare Conference| DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 4, 2014--
Covidien
plc (NYSE: COV) will present at the 2014 Leerink Global Healthcare
Conference in New York on Feb. 12. Coleman N. Lannum, vice president,
Investor Relations, will discuss the company in a presentation scheduled
to begin at 11:05 a.m. ET.
A live audio webcast of the presentation can be accessed at Covidien’s
Investor Relations website: http://investor.covidien.com.
An archived ... |
| | | | 01/28/14 | Valiant Captivia Thoracic Stent Graft System From Medtronic Receives FDA Approval for Treating Aortic Dissections| Supported by Recently Presented Study Results, New Indication Expands Treatment Options for Patients with Dangerous Tear in Upper Segment of Body's Main Artery MINNEAPOLIS -- Jan. 28, 2014 -- Continuing to expand the role of endovascular aortic repair, Medtronic, Inc. (NYSE: MDT) has received approval from the U.S. Food and Drug Administration (FDA) for the Valiant Captivia Thoracic Stent Graft System to be used in the treatment of type B aortic dissections, a serious cardiovascular condition a... |
| | | | 01/28/14 | Medtronic Relocates Its Regional Headquarters to Dubai| Committed to Healthcare Education with its Leading Medical Technology Innovations Dubai, UAE - 28 January 2014, Medtronic, Inc. (NYSE: MDT), the world's largest medical technology company, providing therapies to treat many conditions including cardiac and vascular diseases, diabetes, neurological and spinal conditions, today announced the relocation of its regional Middle East and Africa (MEA) headquarters to Dubai. The company will relocate all its regional operations to TECOM Investment's ... |
| | | | 01/27/14 | Covidien Receives Japanese Regulatory Approval for Reinforced Stapling Reload Technology| DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 27, 2014--
Covidien
plc (NYSE: COV) today announced that its Japanese subsidiary, Covidien
Japan Inc., has received Shonin approval from the Japanese Ministry of
Health, Labor and Welfare for its Endo GIA™ Reinforced Reload with
Tri-Staple™ technology. This approval extends Covidien’s
industry-leading portfolio of advanced surgical staplers and represents
a return by the company to the Japanese stapling buttr... |
| | | | 01/27/14 | Covidien Chief Financial Officer Charles Dockendorff to Retire at End of Year| DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 27, 2014--
Covidien
plc (NYSE: COV) today announced that Charles J. Dockendorff, executive
vice president and chief financial officer, has decided to retire from
the company at the end of this year.
The company anticipates naming Dockendorff’s successor following a
review of candidates, both internal and external. Dockendorff will
assist with the search process and plans to serve as an advisor to the
... |
| | | | 01/24/14 | Covidien Reports First-Quarter Fiscal 2014 Results| Net sales up 3% (up 5%, excluding foreign exchange rate movement);
Medical Devices sales up 3% (up 6%, excluding foreign exchange rate
movement)
First-quarter diluted GAAP earnings per share were $0.87; excluding
specified items, adjusted diluted earnings per share were $1.00
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 24, 2014--
Covidien
plc (NYSE: COV) today announced financial results for the first quarter
... |
| | | | 01/23/14 | Court Rules in Favor of Covidien in Ethicon Patent Infringement Lawsuit| DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 23, 2014--
Covidien
plc. (NYSE: COV) does not infringe certain patents held by Ethicon
Endo-Surgery, Inc., a Johnson & Johnson company, according to a summary
judgment ruling issued by the U.S. District Court, Southern District of
Ohio. As a result of this ruling, the Ethicon patent infringement action
is dismissed and Covidien remains free to continue selling its
Sonicision™ cordless ultrasonic dissection sy... |
| | | | 01/23/14 | Covidien Launches Advanced Medical Training and Education Center in India| State-of-the-Art Innovation Center Opens in Mumbai
MUMBAI, India--(BUSINESS WIRE)--Jan. 23, 2014--
Further developing its capabilities in a key emerging market, Covidien
(NYSE:COV) has officially opened its first training and education center
in India. The Covidien Center of Innovation India (CCI India), located
in Mumbai, offers clinicians training on advanced procedures and
techniques using leading equipment and technology.
“This cen... |
| | | | 01/22/14 | Medtronic Statement on U.S. Supreme Court Ruling in Medtronic, Inc. v. Mirowski Family Ventures| MINNEAPOLIS - Jan. 22, 2014 - Medtronic, Inc. (NYSE: MDT) announced that the U.S. Supreme Court ruled 9-0 in favor of Medtronic that the burden of proving infringement rests with the party asserting a product infringes, even if a license exists between the patent holder and product manufacturer. The ruling came in the case of Medtronic, Inc. v. Mirowski Family Ventures."We are very pleased with the Court's unanimous ruling, which affirmed in this case there is no reason burden of proof law... |
| | | | 01/22/14 | Medtronic SureScan® Pacing Systems First to Be Approved for Full Body MRI Scans Without Positioning Restrictions| Data Verifies Safety of MRI Scans for Any Region of the Body in Patients with Medtronic SureScan®Pacing Systems MINNEAPOLIS - January 22, 2014 - Medtronic, Inc. (NYSE: MDT), today announced that the Medtronic SureScan® pacing systems - the first and only pacing systems in the United States that have been approved by the U.S. Food and Drug Administration (FDA) for use with magnetic resonance imaging (MRI) - are now approved for MRI scans positioned on any region of the body. Patients implanted w... |
| | | | 01/22/14 | Covidien Receives U.S. Food and Drug Administration Clearance for LigaSure™ Maryland Jaw| New device provides one-step vessel and tissue sealing
Improves efficiency during laparoscopic and open procedures
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 22, 2014--
Expanding its industry-leading vessel and tissue sealing portfolio, Covidien
(NYSE:COV) received U.S. Food and Drug Administration (FDA) 510(k)
clearance for the LigaSure™ Maryland jaw open/laparoscopic
sealer/divider. In addition, Covidien completed all European
requirement... |
| | | | 01/21/14 | Covidien to Exit OneShot™ Renal Denervation Program| DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 21, 2014--
Covidien
plc (NYSE: COV) today announced it will exit its OneShot™ Renal
Denervation program. This voluntary action is primarily in response to
slower than expected development of the renal denervation market.
The OneShot system is an over-the-wire balloon-based irrigated catheter
technology for the treatment of hypertension. The system received CE
Mark in February 2012 and is not approved ... |
| | | | 01/17/14 | Medtronic CoreValve® System Obtains Early FDA Approval on Exceptional Clinical Performance| Self-Expanding Aortic Valve Serves Broad Spectrum of Potential Transcatheter Aortic Valve Replacement (TAVR) Patients Who Are Unable to Undergo Surgery MINNEAPOLIS - Jan. 17, 2014 - Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug Administration (FDA) approval of the self-expanding transcatheter CoreValve® System for severe aortic stenosis patients who are too ill or frail to have their aortic valves replaced through traditional open-heart surgery. Untreated, these patients ha... |
| | | | 01/16/14 | Covidien Declares Quarterly Cash Dividend| DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 16, 2014--
Covidien
plc (NYSE: COV) today announced that its Board of Directors has
declared a quarterly cash dividend of $0.32 per ordinary share. The
dividend is payable on February 20, 2014, to shareholders of record on
January 28, 2014.
About Covidien
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and de... |
| | | | 01/15/14 | Covidien Completes Sale of Confluent Surgical to Integra LifeSciences| DUBLIN--(BUSINESS WIRE)--Jan. 15, 2014--
Covidien
plc (NYSE: COV) today announced that it has completed the sale of
its Confluent Surgical product line to Integra LifeSciences Corporation
for approximately $235 million in cash. In addition, Covidien may
receive up to an additional $30 million, contingent upon the achievement
of certain performance measures related to the transition of the
Confluent Surgical product line to Integra.
... |
| | | | 01/15/14 | Medtronic to Appeal Federal District Court Verdict| MINNEAPOLIS - Jan. 15, 2014 - A jury in the Federal District Court of Delaware today decided in favor of Edwards Lifesciences, ruling that the Medtronic (NYSE:MDT) CoreValve® System infringed on Edward's Cribier patent (US Pat. No. 8,002,825). Medtronic intends to appeal. "While we are disappointed in the jury's verdict, we continue to believe that this decision will be overturned on appeal," said Neil Ayotte, vice president and acting general counsel at Medtronic. "Medtronic has... |
| | | | 01/14/14 | HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues| Fourth Quarter 2013 Revenues Approximately $53 Million; up 62% from Q4 in 2012; 2013 Preliminary Revenues Approximately $208 Million; 87% increase from 2012
FRAMINGHAM, Mass., Jan. 14, 2014 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it expects revenues for the fourth quarter of 2013 will be approximately... |
| | | | 01/13/14 | Covidien Announces Transactions Aimed at Emerging Markets ‘Value Segment’| Brazil Acquisition, China Joint Venture Enable Company to Address Underserved Markets, Expand Patient Access to Care
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 13, 2014-- Moving decisively to accelerate a key component of its emerging markets strategy, Covidien plc (NYSE:COV) has completed two transactions – one in Brazil and the other in China – that will enable it to help better meet the specific needs of underserved ‘value segment’ markets. The value segment includes markets with hospitals that... |
| | | | 01/09/14 | Covidien, Lightstone Ventures, New Enterprise Associates Announce Series A Investment in FIRE1| New Therapeutic Device Company Launched by The Foundry
DUBLIN, Ireland--(BUSINESS WIRE)--Jan. 9, 2014--
Covidien plc (NYSE: COV), Lightstone Ventures and New Enterprise
Associates (NEA) will jointly invest in a new company launched by The
Foundry, a premier medical device incubator.
The new company, which is called FIRE1 and is based in Dublin, Ireland,
will focus on developing novel therapeutic devices. Series A funding
will provide t... |
| | | | 01/09/14 | Medtronic Announces U.S. Renal Denervation Pivotal Trial Fails to Meet Primary Efficacy Endpoint While Meeting Primary Safety Endpoint| MINNEAPOLIS - January 9, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that its U.S. pivotal trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, failed to meet its primary efficacy endpoint. The trial met its primary safety endpoint, and the trial's Data Safety Monitoring Board (DSMB) concluded that there were no safety concerns in the study. "SYMPLICITY HTN-3 met its primary safety endpoint related to the incidence of major adverse events one month fol... |
| | | | 01/06/14 | Medtronic Announces Acquisition of TYRX, INC., Developer of Solutions for Surgical Site Infections| MINNEAPOLIS - Jan. 06, 2014 - Medtronic, Inc. (NYSE: MDT) today announced that it has acquired TYRX, Inc., a privately held, New Jersey-based developer of implantable combination antibiotic drug and implanted medical devices. TYRX's product offerings include the recently FDA cleared AIGISRx® R Fully Resorbable Antibacterial Envelope, designed to reduce surgical site infections associated with Cardiac Implantable Electronic Devices (CIEDs), and the AIGISRx® N Antibacterial Envelope, for use with... |
| | | | 01/06/14 | Medtronic Begins VICTORY AF Trial of Patients with Persistent or Long-Standing Persistent Atrial Fibrillation| MINNEAPOLIS - Jan. 6, 2014 - Medtronic, Inc. (NYSE:MDT) today announced the first patient has been enrolled in the VICTORY AF clinical trial, a prospective, non-randomized, controlled study of patients with persistent or long-standing persistent atrial fibrillation (AF) undergoing an ablation procedure with Medtronic's Phased Radiofrequency (RF) system. The study will evaluate the safety of this system, while collecting additional effectiveness data. The Medtronic Phased RF System is investigati... |
| | | | 01/06/14 | Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference| MINNEAPOLIS - Jan 6, 2014 - Medtronic, Inc. (NYSE: MDT), the world's leading medical technology company, today announced it will participate in the 32nd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2014, in San Francisco. Omar Ishrak, chairman and chief executive officer of Medtronic will make a presentation about Medtronic beginning at 9:30 a.m. PST (11:30 a.m. CST). A live audio webcast of the presentation will be available on January 13, 2014, by clicking on the Investor... |
| | |
|
